Precision Nanorobotics for Early Diagnosis of Chronic and Oncological Diseases: A Multimodal Approach to Arthritis, Asthma, Tumor's, And Fatty Liver.

NISHA KUMARI[1], ADHYA[2], SUMIT KUMAR PANDEY[3], DR. ANUPAM SINGH[4]
[1, 2] *Bansal institute of engineering and technology Lucknow*
[3] *Assistant Professor, Bansal Institute of Engineering and Technology (Lucknow)*
[4] *Associate Professor, Bansal Institute of Engineering and Technology*

Abstract- ***This comprehensive review explores the impact of late diagnosis on mortality trends in chronic diseases-including arthritis, asthma, fatty liver disease, and tumors (cancer)-from 2015 to 2025, alongside the emerging role of nanobots in disease detection and therapy. Analysis of global data indicates a steady rise in disease-specific deaths, with late diagnosis accounting for approximately 30% of total mortality in these conditions. For arthritis and asthma, delayed recognition and intervention are linked to increased complications and preventable deaths, despite advances in disease-modifying therapies. In fatty liver disease, late diagnosis often results in progression to cirrhosis or hepatocellular carcinoma, with global deaths projected to rise from 1 million in 2015 to over 1.6 million in 2025. Tumor-related deaths show a similar upward trend, with late-stage detection contributing to nearly 3 million deaths annually by 2025.Nanobot and nanotechnology-based approaches are highlighted as transformative tools for early disease detection and targeted therapy. Nanobots enable sensitive biomarker detection, enhanced imaging, and stimuli-responsive drug delivery, improving diagnostic accuracy and therapeutic outcomes in conditions such as fatty liver disease and cancer. Interaction sites for nanobots include hepatocytes, macrophages, tumor vasculature, and specific cellular receptors, allowing for precision medicine approaches. Despite these advances, challenges remain in clinical translation, standardization, and accessibility of nanobot-based diagnostics. The review underscores the urgent need for improved screening, public awareness, and rapid referral systems to reduce diagnostic delays and prevent avoidable deaths. Early detection, combined with innovative nanotechnology, holds promise for reducing the global burden of chronic diseases.***

Indexed Terms- ***Late diagnosis, Chronic diseases Mortality trends, Nanobots, Nanotechnology, Early detection, Targeted therapy, Precision medicine, Disease biomarker***

I. INTRODUCTION

Drexler introduced the idea of self-replicating, programmable nanodevices.. Essentially, these 'nanorobots' would incorporate a design that allows them to clone and assemble themselves, along with any other necessary device to carry out their functions. Since this manufacturing would occur at an atomic level, these nanomachines would have the capability to disassemble any material atom by atom and create entirely new devices. Drexler envisioned a world where nanorobots could undertake tasks such as cleaning the environment and detoxifying the human blood capillary system.

The concepts he proposed regarding nanotechnology suggested potential solutions for current global issues and future challenges, with nearly infinite possibilities once they are brought to market. In addition to the development of health sensors, experiments are also underway involving sensory perception of our environment. Notably, renowned futurist Ray Kurzweil forecasted in 2005 that by 2040, advancements in nanoscience will grant humans immortality and superhuman capabilities.[2] In provocative assertions, Kurzweil claims that nanobots could substitute natural blood cells to treat cancer and back up memories while rejuvenating

aging cells, effectively eliminating dementia. However, this raises an important question: at what point does this enhancement cross the line into forced evolution? As scientists create new life forms and synthesize DNA, what genetic traits will augmented humans pass on? How interconnected will nanorobotics become? Undoubtedly, numerous ethical dilemmas arise concerning the long-term implications of enhancements and health monitoring through nanotechnology.

Wound healing, particularly in regenerative medicine, is another prominent area of interest in nanorobotics. To this end, researchers from DGIST have created a scaffold-based microbot capable of accurately delivering stem cells to injured tissue in a rat's brain. The nickel and titanium-coated microbot effectively transplanted stem cells, which then proliferated and differentiated into astrocytes, oligodendrocytes, and neurons.Additionally, chemically-driven calcium carbonate-based microrobots have reportedly been successful in administering thrombin to stop bleeding in the blood vessels of mouse and pig models.Nanorobots would possess distinct properties and abilities that enable them to manipulate and control materials at the nanoscale, making them exceptionally valuable across various applications and industries.

1.Recent Developments

Recent advances in the design and development of nanorobots have significantly enhanced their capabilities. One significant development has been the arrival of DNA- grounded nanobots, which make programmable, tone- assembling systems by taking use of the versatility of DNA motes. The perfection, rigidity, and kindly low cost of DNA nanotechnology have generated a lot of interest. As useful nanorobots, scientists have created DNA origami structures that fold and manipulate DNA beaches into complex three- dimensional shapes multitudinous conditioning, including targeted drug administration and chemical seeing, have been demonstrated to be executed by these DNA nanobots with exceptional delicacy and effectiveness[7,8,9]
their safety and efficacy for medical uses.One significant progress in this field is the development of DNA nanobots that can react to specific biological stimuli. For instance, scientists have created DNA-based systems that can be programmed to identify particular biomarkers linked to diseases like cancer. When the nanobot detects these biomarkers, it can release therapeutic agents or initiate a physical response to repair damaged tissues These advancements hold immense promise for personalized medicine, where treatments can be customized to fit an individual's genetic profile.

In addition to DNA nanotechnology, other material-based strategies are also advancing rapidly. Recent efforts have concentrated on creating hybrid nanorobots that incorporate various materials, including nanoparticles and polymeric structures, to enhance stability, functionality, and biocompatibility. These hybrid systems are engineered to maneuver through the body, respond to environmental cues, and carry out specific functions such as sensing, drug delivery, or mechanical actuation. The fusion of these advanced materials has not only boosted the performance of nanorobots but has also improved their compatibility with biological systems, increasing.

2. Medical Applications of Nanorobots

The healthcare industry is one of the most exciting and rapidly developing applications for nanorobots.These nanorobots have the potential to transform diagnostics, treatment, and surgical procedures by facilitating highly accurate interventions at the cellular and molecular levels. A particularly exciting aspect of medical nanobotics is the application of nanobots for targeted drug delivery. Conventional drug delivery methods frequently lead to systemic side effects, as drugs cannot be precisely administered in terms of location and dosage. In contrast, nanobots can be designed to transport therapeutic agents and release them solely in the specific areas where they are needed. This localized approach minimizes the likelihood of side effects and enhances the overall effectiveness of treatments .For instance, DNA-based nanorobots have been engineered to target cancer cells. These nanobots can identify specific biomarkers found on the surface of cancer cells, allowing them to differentiate between cancerous and healthy cells. Once a nanobot locates a cancer cell, it can deliver a dose of chemotherapy drugs directly into the cell, thereby reducing damage to surrounding healthy

tissue (Shao et al., 2022). This targeted drug delivery not only boosts the efficacy of cancer treatments but also significantly diminishes the adverse side effects commonly associated with chemotherapy.

In addition to drug delivery, nanorobots are being investigated for their potential in disease diagnostics. Recent research has shown that nanobots can detect and monitor biological markers indicative of diseases like cancer, Alzheimer's disease, and cardiovascular ailments. Nanobots fitted with sensors can be injected into the body to conduct real-time monitoring of disease markers, facilitating early detection and enabling timely treatment. Such diagnostic capabilities could fundamentally change preventive medicine by allowing for the early identification of diseases long before any clinical symptoms manifest.

Moreover, nanorobots may also play a vital role in minimally invasive surgical procedures. Researchers are working on nanorobots that can be remotely operated to carry out delicate tasks within the human body. These tasks can include repairing tissues, removing clots, or even fixing DNA. The precision and control provided by these miniature machines could decrease the necessity for traditional, high-risk surgeries, thereby enhancing patient outcomes and recovery times.

II. REVIEW OF LITERATURE

2018 – Logic-Gated DNA Nanorobots for Targeted Cancer Therapy

In 2018, Douglas et al. pioneered a significant breakthrough in medical nanotechnology by developing logic-gated DNA nanorobots capable of performing targeted drug delivery. These nanorobots were constructed using a DNA origami technique, allowing precise folding of DNA strands into a tubular shape resembling a clamshell. Each nanorobot was embedded with molecular logic gates that responded only to specific biomarkers present on tumor cells, such as nucleolin. Upon recognizing the target, the nanorobot "opened" to release its cargo—thrombin, a blood-clotting agent—to block tumor blood vessels and induce necrosis. This approach demonstrated a highly selective delivery system, sparing healthy cells and minimizing side effects. It marked a transformative step in combining diagnostic sensing and therapy into one platform—coined as "theranostics." The success of this model established a foundation for programmable, autonomous nanodevices in cancer diagnostics and treatment. This innovation also underscored the potential for non-invasive, smart therapies at the cellular level. It remains one of the most cited works in early-stage nanobot-based diagnostics.

2019 – Micro/Nanorobots for Biosensing and Diagnostics

In 2019, Li et al. provided a landmark review that synthesized emerging advancements in the field of micro/nanorobots for biosensing and diagnostics. This comprehensive study offered insights into how these tiny, mobile robotic platforms were being engineered to perform high-precision tasks within complex biological environments. A key focus of the review was on the ability of these micro/nanorobots to autonomously navigate through fluids, such as blood or tissue, using different propulsion mechanisms including magnetic fields, enzymatic reactions, and chemical gradients.

The authors emphasized that these propulsion strategies enabled enhanced control and real-time responsiveness of nanorobots, a critical feature for diagnostic accuracy. The review detailed how nanorobots could be functionalized with molecular probes to detect disease-related biomarkers such as proteins, nucleic acids, or metabolites. Once inside the body, the nanorobots could engage in target recognition, collect diagnostic data, and even transmit that data externally or perform in-situ analysis. This capability pointed toward a new class of diagnostic tools that operated directly at the site of disease onset, facilitating earlier and more accurate detection compared to traditional laboratory methods.

Another major highlight of the review was the potential of nanorobots in point-of-care (POC) diagnostics—compact, fast, and reliable systems that could be used in clinical or even home settings. By eliminating the need for complex sample preparation and external instrumentation, nanorobot-based biosensing represented a shift toward decentralized healthcare. Li et al. also explored the integration of sensing components such as aptamers, antibodies, and fluorescent tags, further increasing the specificity and sensitivity of diagnostic nanorobots.

This work was foundational in mapping the trajectory of future research and development in medical nanorobotics. It not only summarized current capabilities but also forecasted the convergence of artificial intelligence, wireless communication, and advanced materials with nanobotics for smarter and more autonomous diagnostic tools. The review by Li et al. remains a highly cited resource for understanding the broad potential and technical challenges in the evolving field of nanorobotic diagnostics.

2020 – Environmental Impacts and Biocompatibility of Nanobots

In 2020, researchers turned significant attention toward understanding the environmental impact and biocompatibility of nanobots, an area that had previously received less focus compared to functionality and engineering. A pivotal review by Yin et al. (2020) examined how these miniature devices interact with both living organisms and the external environment, highlighting the dual challenge of making nanobots safe for medical use while ensuring they do not contribute to long-term ecological harm.

The article began by discussing the biocompatibility of nanobots, particularly when used in disease diagnostics and therapeutics. Because nanobots often come into direct contact with cells and tissues, materials used in their construction—such as DNA origami, polymers, magnetic particles, and metals—must not provoke immune reactions or toxic effects. Yin et al. reviewed multiple studies where DNA-based nanobots demonstrated excellent biocompatibility, as DNA is naturally degradable and can be designed to disassemble after completing its function. On the other hand, synthetic components like metals or engineered polymers required additional surface modifications (e.g., PEGylation) to avoid immune recognition.

The review also addressed the degradation and clearance mechanisms of nanobots inside the human body. It was noted that for diagnostic applications, especially in chronic disease monitoring, the ability of nanobots to biodegrade or be safely excreted was crucial to avoid accumulation or interference with physiological processes. The authors emphasized the importance of designing “smart” nanobots that could break down under specific physiological conditions (e.g., pH-sensitive linkages) or be magnetically guided out of the system.

From an environmental perspective, Yin et al. raised important questions about the fate of nanobots after they exit the body or are disposed of improperly during manufacturing and clinical use. Although many medical nanobots are designed to degrade, those made with non-biodegradable materials might accumulate in the environment, potentially impacting aquatic ecosystems or entering the food chain. The review advocated for more research into sustainable and biodegradable materials for nanobot design.

Ultimately, the 2020 review by Yin et al. was instrumental in framing the ethical and safety concerns surrounding nanobot deployment. It encouraged the development of standardized testing protocols for biocompatibility and long-term environmental monitoring. By addressing these broader concerns, the article set a foundation for the responsible and safe integration of nanobots into both clinical and public health.

2021 – Breath-Based Diagnostics Using Nanomaterials

In 2021, researchers expanded the scope of nanobots and nanotechnology in diagnostics by exploring their role in non-invasive, breath-based disease detection. A notable review by Li et al. (2021) explored how nanomaterials could be integrated into diagnostic platforms to detect volatile organic compounds (VOCs) in human breath—a promising avenue for diagnosing various diseases including cancer, diabetes, and respiratory infections.

The key focus of the article was on the development of sensor arrays using nanomaterials—like carbon nanotubes, metal-organic frameworks (MOFs), and gold nanoparticles—which exhibit high sensitivity to trace amounts of chemical biomarkers present in exhaled air. These nanosensors mimic biological olfaction systems and are capable of identifying disease-specific VOC patterns. This approach is termed “electronic nose” (e-nose) technology. Li et al. highlighted the advantages of this technology: it is non-invasive, real-time, and potentially cost-

effective, making it ideal for early screening and point-of-care applications. For example, certain types of lung cancer release specific VOCs that can be detected by nanomaterial-based sensors long before symptoms appear or tumors are visible through imaging.

The article emphasized that these breath sensors, when combined with machine learning algorithms, can significantly improve diagnostic accuracy by analyzing complex patterns across multiple biomarkers. Such integration is a stepping stone toward personalized and predictive medicine, enabling healthcare providers to tailor interventions based on individual metabolic signatures. Additionally, the review examined how nanobots and nanomaterials could be incorporated into wearable or portable breath analyzers. These devices could be used not only in hospitals but also at home, providing continuous monitoring for chronic diseases like asthma, COPD, or diabetes.

However, the authors also addressed the challenges of standardizing breath collection techniques and eliminating confounding variables such as diet, environment, or lifestyle factors, which can influence VOC concentrations. They stressed the importance of large-scale clinical trials and cross-validation to ensure reliability and clinical approval of these technologies.

2022 – Biohybrid Nanorobots for Precision Diagnostics

In 2022, the field of nanomedicine witnessed a significant leap forward with the development of biohybrid nanorobots—miniature machines that combine synthetic materials with biological components for improved performance in diagnostic and therapeutic applications. A landmark study by Shao et al. (2022) discussed how integrating biological elements such as bacteria, red blood cells, or even sperm cells into nanorobots could vastly enhance their mobility, adaptability, and biocompatibility, especially in complex biological environments.

The article highlighted how biohybrid nanobots are designed to harness the natural propulsion mechanisms of living cells. For example, bacteria-driven nanorobots utilize flagella for movement and can navigate through bodily fluids more effectively than synthetic motors alone. This self-propelling ability allows them to reach hard-to-access areas, such as tumor cores or deep blood vessels, which is crucial for high-precision disease diagnostics. These nanorobots are equipped with molecular recognition units, such as aptamers or antibodies, which enable them to detect specific biomarkers with exceptional accuracy. Once they encounter their target—like a cancer-specific antigen—they can relay this information via fluorescent signals, magnetic changes, or even drug release, making them ideal for real-time biosensing and early disease detection.

Shao et al. also explored the role of nanomaterial coatings, such as gold nanoparticles or biodegradable polymers, that enhance the stability and functionality of the biological components. These coatings not only protect the nanobot from immune responses but also enable the controlled release of diagnostic agents or imaging dyes upon reaching the target.

A key breakthrough discussed in the paper was the use of magnetically guided navigation. External magnetic fields can direct the movement of these biohybrid nanobots, improving the precision of diagnostics by steering them toward specific tissues or organs of interest. This technique has been especially useful in non-invasive tracking of infections or early-stage tumors. The study emphasized the growing potential of biohybrid nanobots in personalized medicine, where they can be programmed to operate based on an individual's unique biological markers. This level of customization could lead to diagnostic tools that adapt in real-time to changes in the body, opening doors to dynamic disease monitoring. Despite their promise, Shao et al. acknowledged challenges such as scalability of production, standardization of biological-synthetic integration, and long-term biocompatibility. However, the overall conclusion was clear: biohybrid nanobots represent a transformative step toward next-generation diagnostic platforms—combining the intelligence of biology with the precision of nanotechnology.

2023 – Review on Clinical Translation and Challenges

In 2023, a comprehensive review by Moser et al. brought a much-needed perspective on the clinical translation of nanobots for disease diagnostics, moving beyond lab-based innovations toward real-world applications. While previous years focused on the design, propulsion, and sensing mechanisms of nanobots, this review tackled the critical challenges that must be addressed for these devices to be used safely and effectively in clinical settings.

The review identified four key pillars necessary for successful clinical translation: biocompatibility, targeting accuracy, scalability of production, and regulatory approval. Although many nanobots have shown success in preclinical trials (in vitro and in animal models), few have made it to human testing due to these translational bottlenecks.

A central concern discussed was biocompatibility—how the human body reacts to nanobots over time. While biohybrid and DNA-based nanobots offer improved compatibility, immune responses and unintended interactions with non-target tissues remain major obstacles. The authors emphasized the importance of surface modifications, such as PEGylation or biomimetic coatings, to reduce immune activation and improve circulation time in the bloodstream.

The review also examined the issue of precision targeting. Nanobots designed to diagnose diseases must be extremely specific in recognizing disease biomarkers. Moser et al. highlighted advances in the use of aptamers, monoclonal antibodies, and CRISPR-based systems to improve detection accuracy. However, achieving this level of specificity across genetically diverse patient populations remains a challenge.'

On the manufacturing side, the review pointed out that most nanobot fabrication methods are not yet suitable for mass production. Processes like DNA origami, microfluidic synthesis, and biological assembly are often time-consuming and expensive. The authors argued for the development of standardized, scalable production techniques that maintain quality and performance consistency.

Perhaps the most pressing challenge identified was regulatory approval. Because nanobots sit at the intersection of medical devices, pharmaceuticals, and biologics, they don't fit neatly into existing FDA or EMA categories. The review proposed a multidisciplinary framework for evaluation, which includes toxicity studies, pharmacokinetics, ethical oversight, and risk-benefit analysis tailored to nanorobotic technologies.

Despite these hurdles, the review was optimistic. It showcased a few early-phase clinical trials, such as DNA nanostructures used for cancer biomarker detection and magnetic nanorobots guided to specific tumors for diagnostic imaging. These examples were highlighted as signs of the field maturing from proof-of-concept to clinical potential.

III. DISEASES AND THEIR RECEPTOR SITE

Arthritis

Arthritis literally means "joint inflammation." Joints are locations in the body where two bones meet, and arthritis describes any condition causing inflammation, pain, swelling, stiffness, and reduced mobility in these areas. While joint inflammation is the hallmark, arthritis can also affect tendons, ligaments, and other connective tissues. Symptoms may develop gradually or suddenly and can be persistent or intermittent, depending on the type and severity of the disease.

Causes of Arthritis:

Arthritis is a broad term for over 100 conditions that cause inflammation, pain, and damage in the joints and surrounding tissues. The causes of arthritis are diverse and depend on the specific type, but they generally fall into several main categories:

1. Degenerative Causes: Osteoarthritis (OA) is the most common form of arthritis and is primarily caused by the gradual wear and tear of joint cartilage over time. Cartilage is the smooth tissue that cushions the ends of bones in a joint, enabling frictionless movement. When cartilage deteriorates, bones may rub directly against each other, causing pain, swelling, and reduced mobility. Degenerative arthritis, or osteoarthritis (OA), is influenced by several key factors including aging, as cartilage

naturally wears down over time; joint overuse from repetitive motions in certain occupations or sports, which can speed up cartilage breakdown; and obesity, which adds extra stress on weight-bearing joints like the knees and hips, leading to faster degeneration. Previous joint injuries, whether from accidents or sports, can also make joints more susceptible to early and severe damage, while muscle weakness around a joint reduces support and stability, further increasing the risk of OA.

2. Autoimmune Causes: Rheumatoid Arthritis (RA) and related conditions (such as lupus and scleroderma) are caused by the immune system mistakenly attacking the body's own joint tissues. This leads to chronic inflammation, swelling, and eventually destruction of cartilage and bone.The development of autoimmune arthritis is influenced by several mechanisms and risk factors, including genetic susceptibility, with genes like HLA-DRB1 significantly increasing the risk for rheumatoid arthritis (RA) and related conditions. Environmental triggers such as smoking, exposure to specific dusts, and certain infections can initiate autoimmune responses, particularly in individuals who are genetically predisposed. Sex also plays a role, as women are more likely than men to develop autoimmune arthritis. Although RA can occur at any age, it is most commonly diagnosed in middle-aged individuals. Additionally, infections caused by certain bacteria and viruses, such as Porphyromonas gingivalis and the Epstein-Barr virus, are believed to act as potential triggers for autoimmune joint inflammation

3. Metabolic Causes: Gout and related conditions stem from metabolic imbalances, primarily the buildup of uric acid in the blood, which can crystallize and deposit in the joints, causing inflammation and pain. A key mechanism behind gout is hyperuricemia, where high uric acid levels result either from increased production or decreased excretion. Dietary habits also play a significant role, as consuming purine-rich foods like red meat and seafood, along with alcohol and sugary beverages, can elevate uric acid levels. Kidney dysfunction further contributes by impairing the body's ability to eliminate uric acid effectively. Genetic factors may predispose certain individuals to produce more uric acid or excrete less of it, increasing their risk. Additionally, gout is more prevalent in men and tends to become more common with advancing age.

4. Infectious Causes: Infectious (septic) arthritis occurs when bacteria, viruses, or fungi invade a joint, leading to rapid inflammation and potential joint damage. The main mechanisms include direct infection, where microorganisms can enter the joint through the bloodstream, direct injury, or surgery. Common pathogens responsible for this condition include Staphylococcus aureus, Streptococcus species, and Neisseria gonorrhoeae, among others. Key risk factors for infectious arthritis include existing joint diseases, the presence of artificial joints, immunosuppressive conditions (such as HIV or diabetes), recent surgery, intravenous drug use, and advanced age.

IV. SYMPTOMS OF ARTHRITIS

General Symptoms of Arthritis

Most forms of arthritis share a core set of symptoms related to joint inflammation and damage. The primary symptoms include: Joint Pain: Pain is the most common symptom, which may be constant or intermittent. It can affect one or multiple joints and may worsen with movement or after periods of inactivity.Stiffness: Joint stiffness is typically most pronounced in the morning or after periods of rest. In inflammatory types like rheumatoid arthritis, morning stiffness can last for an hour or longer, while in osteoarthritis, it often lasts only a few minutes. Swelling: Joints may appear swollen, feel puffy, or be visibly enlarged. Swelling is often accompanied by tenderness and warmth to the touch. Redness and Warmth: The skin over affected joints may look red and feel warm, especially during flare-ups of inflammation. Loss of Function/Range of Motion: Arthritis can limit how far a joint can move, making daily activities difficult. Severe cases may result in significant loss of function. Tenderness: Joints may be sensitive or painful when touched or pressed. Deformity: Over time, chronic inflammation can lead to joint deformities, such as crooked fingers or toes, or visible changes in joint shape. Weakness and Instability: Muscles around affected joints may weaken, and joints may feel unstable or prone to giving way. Fatigue: Many people with arthritis experience persistent tiredness, which can be severe,

especially in inflammatory types like rheumatoid arthritis.

Figure 1. It illustrate the projected increase in the prevalence of doctor diagnostics arthritis from 2015 to 2025

2. Symptoms depending upon Type of Arthritis

A. Osteoarthritis (OA):

Osteoarthritis is the most common type of arthritis and is primarily a degenerative joint disease. Its symptoms usually develop gradually. People may experience joint pain during or after movement and stiffness, especially after periods of inactivity or upon waking. The affected joints may feel tender when pressed and may produce a grating or crackling sensation during movement. There is often a loss of flexibility, and in some cases, bone spurs (hard lumps) may develop around the joint. Swelling, particularly after physical activity, is also a common symptom. Osteoarthritis typically affects weight-bearing joints such as the knees, hips, and spine, but it can also involve the hands.

B. Rheumatoid Arthritis (RA)

Rheumatoid arthritis is an autoimmune disease that causes chronic inflammation of the joints. Symptoms often begin gradually and may include symmetrical joint swelling and pain, meaning both sides of the body are affected. One of the hallmark signs is prolonged morning stiffness, typically lasting more than 30 minutes and often over an hour. Affected joints may also show warmth and redness. Individuals may experience fatigue, a general feeling of malaise, and sometimes a low-grade fever. Other symptoms include loss of appetite and unintentional weight loss. Over time, the condition can lead to joint deformities such as ulnar deviation or swan neck deformity. In addition to joint-related issues, systemic symptoms like depression or simply feeling unwell can occur. Rheumatoid arthritis often starts in the smaller joints such as the fingers, wrists, and toes, and may later involve larger joints as the disease progresses.

C. Gout:

Gout is caused by the deposition of uric acid crystals in the joints, which leads to sudden and severe joint pain, often occurring at night. Affected joints may show swelling, redness, and warmth, accompanied by extreme tenderness, where even a light touch can be painful. Gout most commonly affects the big toe, but it can also involve other joints such as the ankles, knees, wrists, and fingers.

D. Infectious (Septic) Arthritis:

Septic arthritis results from an infection within the joint and typically presents with a rapid onset of joint pain and swelling, along with warmth, redness, and fever or chills. Movement of the affected joint is often severely limited due to pain. It usually affects a single joint, most commonly the knee or hip, and prompt medical attention is critical to prevent joint destruction. Psoriatic arthritis, which is associated with the skin condition psoriasis, presents with joint pain, swelling, and stiffness. A distinctive feature is dactylitis, or swelling of entire fingers or toes, giving them a sausage-like appearance. Additionally, there may be nail changes, such as pitting or separation of the nail from the nail bed

3. Systemic and Non-Joint Symptoms:

Some types of arthritis, particularly autoimmune forms like rheumatoid arthritis (RA) and lupus, can produce symptoms beyond the joints, reflecting their systemic nature. These may include fatigue and general malaise, low-grade fever, unintentional weight loss, and anemia (a low red blood cell count). In some cases, individuals may experience eye inflammation, skin rashes or nodules, and even lung or heart involvement in more severe instances. These extra-articular symptoms can sometimes precede joint-related signs by weeks or even months.

Interaction Sites of Nanorobots in Arthritis
Nanorobots and nanoparticles are increasingly being engineered to target specific anatomical and cellular sites in arthritic joints, addressing inflammation, cartilage degradation, and bone damage. Their interactions occur at multiple levels, from systemic delivery to localized tissue repair. Below is a detailed analysis of these interaction sites, supported by recent research.

1. Synovium and Synovial Fluid
The synovium-a membrane lining joint cavities-is a primary site of inflammation in rheumatoid arthritis (RA).Nanorobots interact here to modulate immune responses and deliver anti-inflammatory agents.
Arthritis literally means "joint inflammation." Joints are locations in the body where two bones meet, and arthritis describes any condition causing inflammation, pain, swelling, stiffness, and reduced mobility in these areas. While joint inflammation is the hallmark, arthritis can also affect tendons, ligaments, and other connective tissues. Symptoms may develop gradually or suddenly and can be persistent or intermittent, depending on the type and severity of the disease.

Passive Targeting via Leaky Vasculature: Inflamed joints exhibit "leaky" blood vessels, allowing nanoparticles (50–200 nm) to extravasate and accumulate in the synovium (extravasation through leaky vasculature and inflammatory cell–mediated sequestration, ELVIS effect). This enables systemic delivery of drugs like methotrexate (MTX) or siRNA to suppress pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).

Active Targeting of Macrophages: Activated macrophages in the synovium overexpress receptors (e.g., folate receptor, CD44). Nanoparticles coated with ligands like hyaluronic acid (HA) or folic acid bind to these receptors, enabling precise delivery of dexamethasone or siRNA to reprogram macrophages from pro-inflammatory M1 to anti-inflammatory M2 phenotypes.

Enzyme-Driven Navigation in Synovial Fluid: Enzyme-powered nanorobots (e.g., urease-coated nanoparticles) propel through viscous synovial fluid to reach deeper synovial tissues, enhancing drug distribution and retention. Therapeutic Outcomes: Reduced synovitis, decreased cytokine release, and slowed joint damage.

2. Cartilage Matrix Cartilage degradation is central to osteoarthritis (OA). Nanorobots target the cartilage matrix to deliver regenerative agents or inhibit destructive enzymes.

Size-Dependent Penetration: Nanoparticles <10 nm (e.g., peptide-siRNA complexes) penetrate the dense, avascular cartilage matrix, reaching chondrocytes to suppress catabolic enzymes like MMP-13.

Biomimetic Designs: Nanoparticles incorporating cartilage components (e.g., chondroitin sulfate, collagen) bind to damaged cartilage, releasing growth factors (TGF-β, IGF-1) to stimulate repair.

Enzyme-Responsive Release: Nanoparticles degrade in response to cartilage-specific enzymes (e.g., matrix metalloproteinases), releasing drugs like kartogenin to promote chondrogenesis. Therapeutic Outcomes: Enhanced cartilage regeneration, reduced collagen degradation, and improved joint function.

3. Subchondral Bone In advanced arthritis, bone erosion occurs due to osteoclast activation. Nanorobots target bone-resorbing cells or deliver osteoprotective agents.

Osteoclast Targeting: Nanoparticles functionalized with bisphosphonates (e.g., alendronate) bind to hydroxyapatite in bone, inhibiting osteoclast activity and preventing bone loss.

Exosome-Mediated Regulation: Engineered neutrophil-derived exosomes loaded with nanoenzymes (e.g., Prussian blue nanoparticles) scavenge reactive oxygen species (ROS) in bone tissue, reducing oxidative stress and promoting osteoblast activity. Therapeutic Outcomes: Reduced bone erosion, improved bone density, and balanced bone remodeling.

4. Systemic Immune Modulation Nanorobots also interact with systemic immune cells to suppress autoimmune-driven arthritis.Lymph Node Targeting: Nanoparticles loaded with tolerogenic antigens (e.g.,

type II collagen) traffic to lymph nodes, inducing regulatory T cells (Tregs) to suppress autoimmune responses.

Circulating Macrophage Reprogramming: Lipid-polymer nanoparticles deliver IL-10 plasmids to circulating monocytes, polarizing them to anti-inflammatory M2 macrophages before they infiltrate joints. Therapeutic Outcomes: Systemic immune tolerance, reduced autoantibody production, and prevention of disease progression.

5. Overcoming Biological Barriers: Nanorobots are engineered to navigate challenges unique to arthritic joints: Synovial Fluid Viscosity: Enzyme-driven nanorobots (e.g., urease-powered) generate self-propulsion to overcome viscous fluid, improving penetration into cartilage and synovium..

Activation and Detection of Arthritis Using Nanobots

Activation Mechanisms: Nanobots are activated through environmental cues or external stimuli to deliver therapies precisely at arthritic sites:

1. Passive Targeting via Pathological Features
Leaky Vasculature (ELVIS Effect): Inflamed joints exhibit leaky blood vessels, allowing nanoparticles (50–200 nm) to passively accumulate in the synovium. This "extravasation through leaky vasculature and inflammatory cell–mediated sequestration" (ELVIS effect) enables systemic delivery of anti-inflammatory drugs (e.g., methotrexate) to synovial macrophages. Acidic pH and ROS-Rich Microenvironments: Inflammatory sites in arthritis have lower pH and higher reactive oxygen species (ROS). Nanoparticles with pH- or ROS-responsive coatings release drugs (e.g., dexamethasone) selectively in these conditions, minimizing off-target effects.

2. Active Targeting via Biomolecular Ligands
Macrophage-Specific Receptors: Nanoparticles functionalized with hyaluronic acid (HA) or folate target CD44 or folate receptors overexpressed on activated synovial macrophages. For example, HA-coated nanoparticles deliver prednisolone to suppress TNF-α and IL-6 production, Cartilage-Specific Binding: Cationic nanoparticles (e.g., poly-L-lysine–melanin NPs) bind to anionic glycosaminoglycans (GAGs) in cartilage, enabling early detection of cartilage degeneration via photoacoustic imaging (PAI).

3. External Triggers
Magnetic Fields: Au/Fe/Au nanoparticles are guided to inflamed joints using external magnets, where near-infrared (NIR) light then heats the gold shell to accelerate drug release. Enzyme-Driven Propulsion: Urease-powered nanorobots navigate viscous synovial fluid to penetrate cartilage and deliver growth factors (e.g., platelet-rich plasma) for tissue repair.

Detection Strategies
Biomarkers to detect arthritis through nanobots: Arthritis, particularly rheumatoid arthritis (RA), is a chronic inflammatory disease characterized by joint pain, swelling, and progressive destruction of cartilage and bone. The pathogenesis and progression of arthritis are tightly linked to the complex interplay between pro-inflammatory cytokines and acute-phase proteins. Among these, C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) are central players. This review provides a detailed account of their roles, mechanisms, and clinical relevance in arthritis, with references to recent research.

1. C-Reactive Protein (CRP): CRP is an acute-phase protein produced by the liver in response to inflammation. Its synthesis is primarily induced by IL-6, and to a lesser extent, other cytokines. CRP is a widely used biomarker for systemic inflammation and disease activity in arthritis.

C-reactive protein (CRP) plays a significant role in the acute phase response and serves as a key biomarker in inflammatory conditions such as rheumatoid arthritis (RA) and juvenile chronic arthritis (JCA). Interleukin-6 (IL-6), produced at sites of inflammation like the inflamed synovium in RA, stimulates hepatocytes in the liver to synthesize CRP and other acute-phase proteins. As a result, CRP levels in the blood rise rapidly during active inflammation, making it a sensitive and timely marker of disease activity. Elevated CRP levels are closely associated with active joint inflammation and

often correlate with other indicators such as erythrocyte sedimentation rate (ESR) and clinical symptoms. This makes CRP a valuable tool for monitoring disease progression and evaluating response to therapy in patients with RA and JCA. Beyond its role as an inflammation indicator, high CRP levels are predictive of joint damage, increased cardiovascular risk, and overall mortality in patients with chronic inflammatory diseases. Clinically, CRP is often measured alongside IL-6 to provide a more comprehensive assessment of systemic inflammation, as IL-6 directly regulates CRP synthesis. In RA, patients with persistently high CRP levels are typically at greater risk for severe disease progression and joint destruction.

2. Tumor Necrosis Factor-Alpha (TNF-α)

TNF-α is a key pro-inflammatory cytokine produced by activated macrophages, T cells, and other immune cells in arthritic joints.

Tumor necrosis factor-alpha (TNF-α) is a central mediator in the inflammatory response and plays a critical role in the pathogenesis of rheumatoid arthritis (RA) and juvenile chronic arthritis (JCA). As one of the earliest cytokines released during the inflammatory cascade, TNF-α promotes the recruitment and activation of immune cells and stimulates the production of other pro-inflammatory cytokines, including interleukin-6 (IL-6). This activity contributes to the chronic synovial inflammation that is a hallmark of RA. In addition to fueling inflammation, TNF-α plays a direct role in joint damage by stimulating synovial fibroblasts and chondrocytes to produce matrix metalloproteinases (MMPs), enzymes that degrade cartilage and bone. TNF-α also enhances osteoclast formation, accelerating bone erosion. Elevated levels of TNF-α in both blood and synovial fluid are associated with increased disease activity, joint swelling, and pain, and often correlate with IL-6 and CRP levels, highlighting the interconnected nature of the inflammatory response. Clinically, TNF-α has emerged as a pivotal therapeutic target. TNF-α inhibitors such as etanercept, infliximab, and adalimumab are widely used and have proven highly effective in reducing inflammation, preventing joint damage, and improving quality of life in patients with RA. Furthermore, plasma TNF-α concentrations serve as useful biomarkers for assessing disease activity and monitoring therapeutic response.

3. Interleukin-6 (IL-6)

IL-6 is a pleiotropic cytokine with both pro- and anti-inflammatory properties, but in chronic arthritis, its pro-inflammatory actions predominate.

Interleukin-6 (IL-6) is a key driver of the acute-phase response, stimulating the liver to produce C-reactive protein (CRP), serum amyloid A, fibrinogen, and other acute-phase proteins, thereby linking local joint inflammation to systemic effects in arthritis. IL-6 levels are elevated in both the serum and synovial fluid of patients with rheumatoid arthritis (RA), with strong correlations to joint damage and disease severity. It promotes osteoclast differentiation and bone resorption, contributing to the erosive joint changes characteristic of RA. IL-6 also modulates the immune system by influencing the activity of B cells, T cells, neutrophils, and monocytes, perpetuating the inflammatory response. Additionally, it enhances angiogenesis and increases vascular permeability in synovial tissues, leading to pannus formation and edema. Clinically, IL-6 is an important therapeutic target, and IL-6 receptor inhibitors such as tocilizumab have been approved for RA treatment, effectively reducing inflammation, preventing joint damage, and lowering CRP levels. As a biomarker, IL-6 is commonly measured alongside CRP to assess disease activity and predict disease progression in patients with arthritis.

Detection of specific biomarkers like TNF-alpha and IL-6

1. TNF-α Detection

a. Gold Nanoparticle (AuNP)-Based SERS

Mechanism: AuNPs functionalized with TNF-α antibodies enhance surface-enhanced Raman spectroscopy (SERS) signals. When TNF-α binds to the antibodies, the Raman signal is amplified by a factor of 10^5, enabling label-free detection at physiological concentrations. Performance: Detects TNF-α with high specificity in complex biological fluids (e.g., serum).

b. Gold Nanocluster (AuNC) Immunoassays

Mechanism: Streptavidin-conjugated AuNCs bind TNF-α antibodies for western blot or immunoassay

detection. Performance: Linear detection range <1.25 ng/mL, suitable for cell lysates and clinical samples.

2. IL-6 Detection
Electrochemical Biosensors
Mechanism: Platinum carbon electrodes are modified with AuNPs and 4-mercaptobenzoic acid (4-MBA). IL-6 antibodies are attached via EDC/NHS chemistry, enabling antigen-specific binding.
Performance:The multiplexed optical platform known as AVAC demonstrates a linear detection range of 100–700 pg/mL and achieves a detection limit as low as 3 pg/mL, outperforming traditional ELISA methods in clinical samples. It offers high specificity against common interferents such as bovine serum albumin (BSA) and glutathione. The mechanism involves the use of gold nanoparticles (GNPs) of varying sizes—80 nm, 100 nm, and 150 nm—to enable the simultaneous detection of interleukin-6 (IL-6), cardiac troponin I (cTnI), and B-type natriuretic peptide (BNP). For IL-6 specifically, the platform achieves a remarkably low detection limit of 0.16 pg/mL with a dynamic range extending from 0.16 to 850 pg/mL.

3. CRP Detection:
Carbon nanotube (CNT) field-effect transistors (FETs) utilize aptamer-functionalized CNTs to detect C-reactive protein (CRP) by measuring changes in electrical conductivity upon target binding. These sensors demonstrate a linear detection range of 0.43–42.86 nM (equivalent to 0.05–5 mg/L) and achieve a low detection limit of 150 pM (0.017 mg/L). Nanorobot-based detection technologies offer several key advantages, including exceptional sensitivity, capable of detecting biomarkers at ultra-low concentrations such as 3 pg/mL for interleukin-6 (IL-6). They also provide rapid results, delivering CRP measurements in 8 minutes or less.

V. DISEASES AND THEIR RECEPTORS SITE

Asthma
Asthma is a chronic inflammatory disease of the airways in the lungs. It is characterized by episodes of wheezing, coughing, chest tightness, and shortness of breath, which can vary in severity and frequency. During an asthma attack, the airways become swollen, constricted, and often filled with excess mucus, making it difficult to breathe. These symptoms are usually triggered by various factors such as allergens, infections, exercise, or exposure to irritants like smoke or pollution. The airflow obstruction in asthma is often reversible, either spontaneously or with treatment, but the underlying inflammation persists over time.

Causes of Asthma
1. Genetic Predisposition
Family History: Having a parent with asthma increases an individual's risk of developing the condition by three to six times compared to those without a parental history. Asthma is also more common among individuals with a family history of atopic conditions, such as eczema and allergic rhinitis (hay fever). Genetic susceptibility plays a significant role in asthma development, with specific genes involved in immune regulation, airway responsiveness, and inflammation contributing to increased risk. Additionally, phenotypic differences—such as childhood-onset versus adult-onset asthma—may be influenced by genetic factors, which can affect both the severity of the disease and the response to treatment.

2. Environmental Factors
Allergens:Indoor allergens such as dust mites, pet dander, cockroach allergens, and mold are common asthma triggers, particularly in urban environments. Outdoor allergens, including pollen from trees, grasses, and weeds, as well as outdoor molds, can also provoke asthma symptoms. Exposure to air pollution—specifically ozone (smog), nitrogen dioxide, and particulate matter—not only increases the risk of developing asthma but also worsens existing symptoms. Urbanization is linked to a higher prevalence of asthma due to increased contact with pollutants and allergens. Tobacco smoke is another major risk factor, with both active smoking and exposure to secondhand smoke—especially during pregnancy and early childhood—contributing to the development and severity of asthma. Maternal smoking during pregnancy is especially detrimental, significantly raising the risk of childhood asthma.

Respiratory Infections: Severe viral respiratory infections in infancy or early childhood (e.g., respiratory syncytial virus, parainfluenza) can

damage developing airways, increasing the risk of chronic asthma.

3. Diet and Lifestyle

Diets high in red meat and low in nuts are associated with increased asthma risk in children. Alcohol consumption, particularly wine, can trigger asthma symptoms in susceptible individuals. Lack of early exposure to common infections (hygiene hypothesis) may increase asthma risk by altering immune system development.

4. Pathophysiological Mechanisms

Asthma pathogenesis involves a complex interplay of immune cells—including mast cells, eosinophils, macrophages, and dendritic cells—along with cytokines such as IL-4, IL-5, IL-13, TGF-β, and IL-11, and various inflammatory mediators like histamine, leukotrienes, and prostaglandins. Upon allergen exposure, IgE-mediated activation of mast cells occurs, leading to the release of inflammatory mediators that cause bronchospasm and airway inflammation. If left uncontrolled, chronic inflammation can result in structural changes such as airway remodeling, smooth muscle hypertrophy, and persistent airflow limitation. Additionally, environmental triggers like infections, pollutants, and irritants further amplify the inflammatory response and contribute to increased airway hyperresponsiveness.



Figure 2 The graph illustrate the projected increase in the prevalence of doctor diagnosed asthma.

Asthma Symptoms

Shortness of breath, or dyspnea, is characterized by difficulty breathing or a sensation of breathlessness. It is often ranked as the most challenging symptom for adult patients, with a mean rank of 7.2. Patients frequently describe this experience as "not getting enough air" or "breathing through a straw." Dyspnea can occur during physical activity, at rest, or in response to various triggers. Adults report this symptom as being of high severity, with a mean score of 7.3, indicating the significant impact it has on their daily lives and overall well-being.

1.Chest Tightness: Sensation of pressure, discomfort, or constriction in the chest,Reported by 97.1% of adults and 68.8% of adolescents in concept elicitation interviews, Rated as the most intense symptom by adults (mean severity score = 7.6) Often accompanies or precedes other asthma symptoms, In adolescents, rated as one of the most severe symptoms (mean rating = 6.9).

2.Wheezing: A high-pitched whistling sound during breathing, especially on exhalation, is common in asthma. It is reported by 91.2% of adults and 87.5% of adolescents. The sound is often audible and tends to worsen at night or in the early morning. This symptom is considered a hallmark of asthma in multiple studies. In adults, it has a mean severity score of 7.0.

3.Coughing: Coughing in asthma is often persistent or recurring and may be dry or productive. It is reported by 88.2% of adults and 81.3% of adolescents. This symptom is frequently worse at night or in the early morning. In some individuals, especially children, coughing may be the predominant or only symptom. Adolescents rate coughing as one of their most severe symptoms, with a mean rating of 6.9.

4.Severe Respiratory Distress: During an asthma attack, there is a marked increase in respiratory rate, with the individual breathing faster than normal. The use of accessory muscles for breathing becomes evident, causing visible retractions in the chest. Deep sucking motions at the throat or chest are often observed as the person struggles to breathe. The chest may expand but fail to deflate properly during

exhalation. Additionally, individuals may adopt hunched shoulders or altered posture, known as "posturing," to assist with breathing and alleviate discomfort.

5.Cyanosis and Decreased Oxygen Saturation: Cyanosis, characterized by blue discoloration of the lips, nail beds, or skin, is a sign of oxygen deficiency and indicates severe respiratory compromise, requiring emergency intervention. In very severe cases, it may be accompanied by altered mental status. When asthma symptoms fail to improve with quick-relief medications, such as bronchodilators, or when there is a need for increased or more frequent doses of rescue medication, it suggests worsening airway obstruction and inflammation. This ineffective response to medication highlights the severity of the asthma attack and the need for immediate medical attention.

6.Exhaustion and Distress: During a severe asthma attack, individuals may experience extreme fatigue from the increased effort required for breathing. Anxiety, agitation, or panic can arise due to the sensation of air hunger. In some cases, confusion or drowsiness may occur, signaling carbon dioxide retention and severe hypoxemia. Overall, individuals may feel greatly distressed or exhausted from the constant struggle to breathe

VI. INTERACTION SITES OF NANOROBOTS IN ASTHMA

Nanotechnology offers promising approaches for asthma treatment through targeted drug delivery and novel therapeutic mechanisms. The search results reveal several key interaction sites and mechanisms by which nanorobots and nanoparticles operate in asthma management.

Primary Interaction Sites: Nanoparticles play a significant role in addressing various aspects of asthma by interacting with key components of the airway. In the airway epithelium and mucus layer, nanoparticles such as chitosan (CS) nanocarriers can open tight junctions between epithelial cells, facilitating the transport of protein-loaded therapeutics across the nasal mucosa’s ciliary layer. Special nanogels composed of tris(2-carboxyethyl) phosphine (TCEP) and Arg-grafted CS (CS-Arg) help overcome mucus obstruction in asthmatic airways by disrupting the mucus network. In terms of inflammatory cells, nanoparticles can target specific cells involved in asthma pathogenesis, including eosinophils, neutrophils, dendritic cells, and macrophages, with some formulations selectively affecting certain cell types. Finally, in lung tissue and parenchyma, biomimetic nanoparticles show enhanced targeting retention in inflamed lungs compared to free drug delivery. When inhaled, these nanoparticles are able to reach deeper into the lung parenchyma, improving drug deposition and efficacy compared to conventional delivery methods.

Mechanisms of Action

1. Enhanced Drug Delivery: Nanoparticles protect drugs from rapid degradation and clearance by shielding them from inactivation after administration. They help overcome mucus obstruction in airway inflammatory diseases and, in the case of liposomal nanoparticles (LNPs), offer sustained drug release for up to 24 hours in vitro, thereby extending the therapeutic duration.

2. Immunomodulation: Berberine-loaded biomimetic nanoparticles regulate Th1/Th2 balance by enhancing IL-12 expression, which reduces lung inflammation and allergic asthma.These nanoparticles significantly reduce inflammatory cell infiltration, including eosinophils, neutrophils, and dendritic cells in bronchoalveolar lavage fluid (BALF).

3. Gene Therapy Delivery: Nanoparticles serve as gene transfer vectors that "wrap DNA and RNA in nanoparticles or adsorb them on the surface".They protect genetic material from rapid degradation in the body.Lipid nanoparticles can safely transport genetic material into lung tissue after modifying their size and chemical compositions.

4. Anti-Inflammatory Effects:Heparin encapsulated in chitosan and cyclodextrin nanoparticles "interact with mast cells to reduce inflammation and airway hyper-responsiveness in asthma models".Steroid-encapsulated biocompatible blended nanoparticles produce "prolonged and greater benefits at the site of airway inflammation compared to free steroids".



Figure 3 An Nanocure advanced medical technology platforms that uses nanorobots.

Novel Therapeutic Targets:

1. IL-17 Pathway: Chitosan-recombinant protein IL-17RC (CS-RC) nanoparticles reduce airway inflammation in Th2-low endotype asthma, which is characterized by neutrophil infiltration and IL-17 pathway activation.

2. Oxidative Stress: Metallic nanoparticles like gold nanoparticles (AuNPs) can minimize asthma symptoms through "suppression of the secretion of proinflammatory cytokines and chemokines, in a mechanism probably related to the downregulation of oxidative stress levels".

3. Bacterial Targets: CS-Arg nanoparticles "target the bacterial anion and significantly inhibited the growth of S. aureus", addressing bacterial components that may exacerbate asthma.

Activation and Detection of Asthma Using Nanobots:

Nanotechnology represents a frontier in asthma management, offering innovative approaches for both therapeutic intervention and diagnostic capabilities. This review examines how nanobots (nanoparticles and nanosystems) can be activated within asthmatic airways and utilized for enhanced detection of asthma, based on current research findings.

1. Targeted Drug Delivery Systems

Direct Pulmonary Administration: Inhaled nanocarriers loaded with drugs or nucleic acids can pass through the bronchial tract and directly reach the lungs, acting on the site of injury in asthmatic airways. This targeted approach avoids the first-pass effect and improves bioavailability compared to systemic administration.

Enhanced Retention and Deposition: Nanoparticles increase therapeutic effect by facilitating the delivery of drugs to target tissue, thereby improving deposition in the lungs. Thiolated chitosan nanoparticles and nanoparticles containing chitosan and cyclodextrin have been used as lung delivery systems to prolong drug retention in the respiratory tract and enhance their anti-inflammatory effect.

2. Receptor-Mediated Targeting

Epithelial Cell Targeting: Airway epithelial-targeting ligands, such as anti-intercellular adhesion molecule-1 (anti-ICAM-1) and anti-epithelial adhesion molecule (anti-EpCAM), can be covalently attached to nanoparticle surfaces to guide them to epithelial cells while bypassing unwanted internalization into immune cells.

ICAM-1 Targeted Systems: Researchers have developed ICAM-1 targeted nanocomplex vector systems to mediate gene transfection of the airway epithelium in vitro and in vivo. These lipid-based nanoparticles selectively internalize into airway epithelial cells, leading to efficient transfection and restoration of gene expression.

3. Gene Therapy Delivery

Nanoparticle Gene Carriers: Nano-sized gene carriers function as gene transfer vectors that "wrap DNA and RNA in nanoparticles or adsorb them on the surface of nanoparticles". These carriers protect genetic material from rapid degradation in the body.

Chitosan-Based Systems: Chitosan-IFN-γ pDNA nanoparticles (CIN) significantly reduce airway hyperresponsiveness and lung histopathology in BALB/c mice with allergic asthma induced by ovalbumin. CIN effectively inhibits the production of pro-inflammatory factors in lung OVA-specific CD8+ T lymphocyte populations and lowers the activation level of dendritic cells.

4. Immunomodulatory Mechanisms

Cytokine Regulation: Anti-IL4Rα nanoparticles meaningfully reduce proinflammatory cytokine expression and release in bronchoalveolar lavage fluid (BALF) and lung tissue. These nanoparticles deactivate CD4 and CD8 T cells in lung tissue and inhibit their capacity to generate proinflammatory cytokines.

Th1/Th2 Balance Modulation: CIN treatment effectively regulates Th1/Th2 immune response. Once regulatory T cells detect up-regulation of IFN-γ expression, they up-regulate the expressions of Th1 cytokines and down-regulate the expressions of Th2 cytokines.

Detection of Asthma Using Nanotechnology:
1. Biomarker Detection Systems
Electronic Nose Technology: E-nose can be used to detect patients with eosinophilic, neutrophilic, and paucigranulocytic asthma phenotypes according to their breath prints. While not explicitly nanobot-based, this represents the direction of nanotechnology in asthma phenotyping.

Inflammation Monitoring: Nanotechnology enables the development of special nanoparticles for detection of inflammatory changes in asthmatic airways. These can be used to track therapeutic responses and disease progression.

2. Cellular Response Monitoring
Macrophage Migration: In ovalbumin (OVA)-induced asthma models, gold nanoparticle (AuNP)-loaded macrophages migrate to the lung tissue. Macrophages loaded with AuNPs exhibited a sixfold faster migration into the lung tissue in the OVA-severe model compared to the OVA-asthma model, providing a potential means for monitoring disease severity.

Airway Responsiveness Assessment: Nanoparticle systems can be used to assess airway hyperresponsiveness, a key feature of asthma, providing more detailed information than conventional methods.

Nanorobots detect specific biomarkers for detection of asthma :
1.Fractional Exhaled Nitric Oxide (FeNO):
FeNO represents one of the most established biomarkers for asthma diagnosis and monitoring. It is "a convenient, easy-to-obtain, and non-invasive method for assessing active, mainly Th2-driven, airway inflammation, which is sensitive to treatment with standard anti-inflammatory therapy". Studies have demonstrated its diagnostic value, with one research establishing a cut-off value of 64 ppb (sensitivity 52.0%, specificity 94.35%) for asthma diagnosis in bronchoprovocation test patients.

Nanotechnology applications for FeNO detection Nanosensor arrays: These consist of metal oxide semiconductors (often tin oxide or tungsten oxide) at nanoscale dimensions that change electrical resistance when exposed to nitric oxide in exhaled breath.Field-effect transistor (FET) biosensors: Carbon nanotube-based FETs functionalized with NO-specific binding molecules provide enhanced sensitivity for FeNO detection compared to conventional chemiluminescence analyzers. Quantum dot fluorescence sensing: Nanoparticles with quantum confinement properties change their fluorescence properties in proportion to NO concentration, allowing optical detection of FeNO.The integration of these nanosensors into portable devices enables point-of-care testing with detection limits approaching parts-per-billion levels, comparable to clinical FeNO analyzers but in potentially more accessible formats.

2.Interleukins and Th2 Cytokines:
Interleukins, particularly IL-4, IL-5, and IL-13, are central to the Th2 inflammatory pathway characteristic of allergic asthma. Research has identified IL18R1 as a promising biomarker, with evidence showing it is "upregulated in serum and induced sputum and bronchoalveolar lavage fluid of patients with uncontrolled or severe asthma".

Nanotechnology approaches for interleukin detection: Antibody-conjugated nanoparticles: Gold nanoparticles functionalized with antibodies specific for various interleukins enable colorimetric or electrochemical detection.Aptamer-based nanosensors: DNA or RNA aptamers with high affinity for specific interleukins, conjugated to nanoparticles, allow for selective detection through conformational changes or electrochemical signaling.Multiplexed nanoarrays: Nanoparticle-based arrays capable of simultaneously detecting multiple interleukins (IL-4, IL-5, IL-13) provide comprehensive Th2 cytokine profiling from small sample volumes.These nanotechnology platforms offer significant advantages over traditional ELISA-based methods, including improved sensitivity (detecting picogram/mL concentrations), reduced

sample volume requirements, and faster analysis times.

3.Eosinophil Cationic Protein (ECP): ECP is a marker of eosinophil activation that has shown promise for detecting Type-2 inflammation in asthma. Studies suggest that "plasma concentrations of eosinophil cationic protein (ECP), a marker of eosinophil activation, would be useful for detection of Type-2 inflammation and would predict poorer asthma outcomes over one year".

Nanotechnology-based ECP detection systems:Magnetic nanoparticle immunoassays: Superparamagnetic iron oxide nanoparticles conjugated with anti-ECP antibodies enable magnetic separation and quantification of ECP from complex biological matrices.Surface plasmon resonance (SPR) nanosensors: Gold nanostructures with surface plasmon resonance properties provide label-free, real-time detection of ECP binding events.Electrochemical impedance spectroscopy (EIS): Nanopatterned electrodes modified with ECP-specific antibodies detect changes in interfacial electron transfer resistance upon ECP binding.These approaches offer improved sensitivity compared to commercial immunoassays, with detection limits in the sub-nanogram range, facilitating earlier identification of eosinophilic inflammation.Integrated Nanosystems for Comprehensive Asthma Biomarker ProfilingAdvanced nanotechnology platforms are being developed to integrate multiple biomarker detection capabilities.

Disease and their receptors site

Fatty liver
There are two main types of fatty liver disease:
Nonalcoholic fatty liver disease (NAFLD): This type occurs in people who drink little or no alcohol. NAFLD is now the most common chronic liver disease worldwide, especially in people who are overweight, have type 2 diabetes, high cholesterol, or metabolic syndrome. NAFLD ranges from simple steatosis (fat in the liver without inflammation or cell damage) to non-alcoholic steatohepatitis (NASH), where there is fat, inflammation, and liver cell injury, which can progress to cirrhosis or liver cancer.

Alcoholic fatty liver disease (AFLD): This type is caused by heavy alcohol use. The liver breaks down alcohol, but the process produces substances that can damage liver cells and promote fat buildup. Continued drinking can lead to alcoholic hepatitis and cirrhosis.

Causes of fatty liver
1.Obesity and Metabolic Disorders: Obesity, particularly abdominal obesity, is the most common cause of fatty liver. Individuals who are overweight (BMI 25–30) or obese (BMI >30) are at a significantly higher risk. Type 2 diabetes and insulin resistance further increase susceptibility, as they lead to increased fat storage in the liver. Dyslipidemia, marked by high cholesterol and triglycerides, also contributes to liver fat buildup.

2.Alcohol Consumption: Excessive alcohol intake is the primary cause of AFLD. Alcohol metabolism produces harmful byproducts that promote fat accumulation and liver damage. While heavy drinking is the major risk factor, even moderate alcohol use can aggravate NAFLD.

3.Nutritional Imbalance and Weight Changes: Rapid weight loss from crash diets or bariatric surgery can unexpectedly lead to fatty liver due to increased fat mobilization. Malnutrition, starvation, and long-term IV feeding can disrupt fat metabolism and also contribute to liver fat accumulation.

4.Medications and Toxins: Certain medications, including amiodarone, methotrexate, tamoxifen, corticosteroids, and antiretroviral therapies, are known to induce fatty liver. Environmental toxins, such as those from certain mushrooms or phosphorus exposure, can also harm the liver.

5.Genetic and Other Risk Factors: Inherited metabolic disorders (e.g., lipodystrophy, glycogen storage diseases) and genetic predisposition can cause fatty liver, even in the absence of lifestyle-related risk factors. The condition is more common with advancing age, and smoking further elevates the risk. Notably, fatty liver can also develop in younger individuals and children without the presence of traditional risk factors.

Interaction Sites of Nanorobots in Fatty Liver Disease

1.Primary Interaction Sites:

Hepatocytes: Hepatocytes serve as crucial targets for nanotherapeutics in fatty liver disease. Galactose-modified delivery systems specifically target hepatocytes by recognizing asialoglycoprotein receptors (ASGPR) expressed on their surface. This targeting strategy is particularly valuable as ASGPR expression is fibrosis stage-dependent, enabling precise treatment calibration based on disease progressionIn vitro studies demonstrate that self-assembled rosuvastatin-loaded nanoparticles significantly reduce intracellular triglycerides and cholesterol accumulation in hepatocytes. Similarly, fenofibrate-loaded polymer-lipid hybrid nanoparticles achieve higher drug-loading efficiency through π–π stacking interactions, effectively reducing hepatic lipid accumulation by upregulating PPARα expression.

Macrophages and Kupffer Cells: As illustrated in the provided image, nanoparticles interact extensively with liver macrophages (Kupffer cells). These cells play a crucial role in nanoparticle uptake, with studies showing that up to 90% of administered nanoparticles co-localize with liver macrophages.The image demonstrates how nanoparticles can induce polarization of pro-inflammatory M1 macrophages toward anti-inflammatory M2 phenotypes, addressing a key pathological feature of fatty liver disease.Water-based polyurethane nanoparticles inhibit M1 polarization by reducing inflammatory cytokine secretion, including IL-1β, TNF-α, and IL-6.Similarly, dextran-based nanocarriers combined with dexamethasone effectively shift macrophages to an anti-inflammatory phenotype, improving liver inflammation and fibrosis.

Hepatic Stellate Cells (HSCs): Nanoparticles can target activated hepatic stellate cells, which play a central role in liver fibrosis development. Gold nanorods with surface-modified anti-PDGFRβ specifically target activated HSCs, enabling targeted therapy and photothermal ablation to reduce hepatic inflammation and regress fibrosis

Nanoparticles can target multiple metabolic pathways disrupted in fatty liver disease:

Autophagy regulation: Nifedipine-loaded polymeric nanoparticles prevent accumulation of autophagy-related proteins by restoring cytosolic calcium balance, alleviating insulin resistance and reducing hepatic steatosis.

Mitochondrial function: Acid-activated nanoparticles (acNPs) restore lysosomal acidity, reactivating autophagy and improving mitochondrial function, ultimately reversing fasting-induced hyperglycemia and hepatic steatosis

ROS Neutralization and Anti-inflammatory Effects: As shown in the image, ROS generation plays a significant role in fatty liver pathogenesis. Nanoparticles with antioxidant properties, such as cerium oxide nanoparticles (shown in the upper right of the image), can neutralize ROS and reduce oxidative stress. Fenofibrate-loaded nanoparticles effectively suppress oxidative stress via synergistic antioxidant effects.

Advanced Therapeutic Approaches:

Nucleic Acid Delivery: Nanomaterials play a crucial role in delivering therapeutic nucleic acids that target key pathways involved in fatty liver disease. Lipid nanoparticles have been used to deliver CTP cytidylyltransferase α (CCTα) mRNA, which promotes phosphatidylcholine synthesis. This helps reduce lipid accumulation, inflammation, and fibrosis in the liver. Additionally, nanoparticles carrying siRNA targeting the inositol-requiring enzyme 1α (IRE1α) and X-box binding protein 1 (XBP1) pathway have shown promise in decreasing lipid buildup and restoring intestinal barrier integrity.Protein Therapeutics: Innovative nanocarrier systems, such as self-assembling nanoparticles composed of chitosan, metformin, penetratin, and DSPE-PEG, have been developed to deliver protein therapeutics like interleukin-22 (IL-22) directly to the liver. This approach has demonstrated improvements in glucose tolerance and insulin sensitivity, while also reducing hepatic steatosis, offering a promising strategy for treating metabolic aspects of fatty liver disease.

Symptoms of Fatty Liver Disease:

Fatty liver disease (FLD), also called hepatic steatosis, is a condition where excess fat accumulates in the liver. It is often silent in its early stages, but as the disease progresses, a range of symptoms and complications may develop. These symptoms can vary depending on the severity of liver involvement, the presence of inflammation or fibrosis, and whether the disease is nonalcoholic (NAFLD/MASLD) or alcohol-related (AFLD/ASH). This review provides a detailed, referenced account of the symptoms of fatty liver disease, including both mild and advanced stages.

1.Early and Mild Symptoms:In the initial stages, fatty liver disease—both nonalcoholic (NAFLD) and alcohol-related (AFLD)—is usually asymptomatic. Many individuals are diagnosed incidentally during routine blood work or imaging conducted for unrelated health issues. Despite silent progression, some may experience vague, non-specific symptoms such as persistent fatigue, general malaise, poor concentration, mild unintentional weight loss, and sleep disturbances like insomnia or daytime sleepiness. Mild abdominal symptoms, including a dull ache or discomfort in the upper right side of the abdomen and a feeling of bloating or fullness, can also occur.

2.Symptoms of Progressive or Advanced Disease:As fatty liver disease advances to more severe forms like steatohepatitis (NASH/MASH or ASH), fibrosis, or cirrhosis, symptoms become more pronounced. Liver-related signs include abdominal swelling (ascites), swelling of the legs (edema), an enlarged liver (hepatomegaly), and an enlarged spleen (splenomegaly). Skin and mucosal changes, such as jaundice, itchy skin, easy bruising, spider angiomas, and red palms (palmar erythema), may also develop. Gastrointestinal and systemic symptoms become more evident, including nausea, appetite loss, significant unintentional weight loss, dark urine, pale stools, vomiting blood, or black stools. Mental confusion or drowsiness due to hepatic encephalopathy may emerge in severe stages.

3.Other Common and Associated Symptoms:Neuropsychiatric symptoms, such as anxiety and depression, are frequently reported among individuals with NAFLD. Sleep disorders—including insomnia and poor sleep quality—are also prevalent and contribute to overall fatigue. Additionally, symptoms related to metabolic syndrome, such as obesity, diabetes, high cholesterol, and hypertension, commonly coexist and intensify the disease burden.

4.Complications and Warning Signs: If left unmanaged, fatty liver disease can lead to life-threatening complications. Cirrhosis involves extensive liver scarring and can result in liver failure and an elevated risk of liver cancer (hepatocellular carcinoma). Esophageal varices—swollen veins in the esophagus—may also develop and pose a serious bleeding risk, representing a critical and potentially fatal complication.



Figure 4 Fatty Liver Disease:Total Deaths vs. late Diagnosis-Related Deaths(In Thousands)

VII. ACTIVATION AND DETECTION OF FATTY LIVER DISEASE USING NANOBOTS:

Nanotechnology presents innovative and non-invasive strategies for detecting fatty liver disease (NAFLD/MASLD). Advanced nanoparticle systems function as powerful diagnostic tools through several mechanisms. One such approach involves biomarker detection, where nanobots are engineered to recognize specific NAFLD indicators. For instance, biomarkers like hyaluronic acid (HA) and pentraxin 3 (PTX3) have shown potential in identifying various

stages of NAFLD, particularly the progression of fibrosis.

Another application is in in vitro diagnostic models. Nanoparticle-based systems are utilized to develop laboratory models that accurately replicate key features of NAFLD, such as steatosis, oxidative stress, inflammation, and impaired liver function. These models enhance the ability to detect the disease at earlier stages and facilitate research into its mechanisms.

Beyond diagnostics, nanotechnology plays a significant role in therapeutic activation mechanisms. Nanobots can initiate therapeutic effects through targeted drug delivery and precise cellular interactions. One example is acid-activated nanoparticles (acNPs), which help restore lysosomal acidity in NAFLD-affected hepatocytes. This restoration improves autophagic flux, boosts mitochondrial activity, and reduces lipid droplet accumulation and triglyceride levels in liver cells.
Various drug-loaded nanoformulations are designed to deliver therapeutic agents directly to the liver. For example, NFD-NPs have been shown to suppress lipid metabolism disorders in MASLD mice, while fenofibrate-loaded polymer-lipid hybrid nanoparticles reduce hepatic lipid accumulation effectively.

Nanoparticles also contribute to inflammation reduction by modulating immune cell behavior, specifically by inducing the polarization of pro-inflammatory M1 macrophages into anti-inflammatory M2 phenotypes. This mechanism is critical in mitigating liver inflammation, reducing inflammasome activation, and preventing fibrosis formation.

Targeting specific cellular receptors further enhances the precision of nanoparticle-based therapies. Gold nanorods modified with anti-PDGFRβ can target activated hepatic stellate cells (HSCs), leading to reduced hepatic inflammation and regression of fibrosis. Similarly, AEAA-modified nanoparticles target the sigma-1 receptor on activated HSCs to deliver gene therapy locally and effectively.Additionally, ROS-responsive systems have emerged as an effective method for addressing oxidative stress in fatty liver disease. Dual-sensitive nanoparticles that respond to both ROS and pH changes, such as PD-MC, have demonstrated the ability to ameliorate liver fibrosis. These systems inhibit inflammatory responses and ROS production, prevent hepatocyte apoptosis, and halt the activation of HSCs and macrophages.

Biomarkers to Detect Fatty Liver Disease Through Nanobots

1.ECM-Related Biomarkers:The Enhanced Liver Fibrosis (ELF) score is a diagnostic panel composed of three biomarkers associated with extracellular matrix (ECM) deposition. These biomarkers include Procollagen III N-Terminal Peptide (PIIINP), Tissue Inhibitor of Metalloproteinase 1 (TIMP1), and Hyaluronic Acid (HA). Nanotechnology can facilitate the detection of these markers with increased precision and sensitivity. Although these biomarkers demonstrate moderate to excellent predictive accuracy for liver fibrosis, current research indicates that the ELF test lacks sufficient sensitivity for detecting early fibrotic stages.

2.Fibrosis and Inflammation Markers:Nanoparticle-based detection systems have also been employed to identify pro-fibrotic and inflammation-related markers. Key markers include Collagen Type I Alpha 1 Chain (Col1a1), Alpha-Smooth Muscle Actin (Acta2), and Connective Tissue Growth Factor (Ctgf). These biomarkers have shown a strong correlation—both positive and negative—with liver fibrosis in studies utilizing the choline-deficient, L-amino acid-defined (CDAA) diet rat model, highlighting their potential for non-invasive diagnosis of fibrosis.

3.Novel Biomarker Detection Systems: Recent advances in computational biology have led to the identification of novel biomarkers using machine learning algorithms. Five key genes have emerged as potential diagnostic indicators for NAFLD: CCAAT Enhancer Binding Protein Delta (CEBPD), Histone H4 (H4C11), CCAAT Enhancer Binding Protein Beta (CEBPB), GATA Binding Protein 3 (GATA3), and Kruppel Like Factor 4 (KLF4). These genes were validated through quantitative real-time PCR and are notably associated with immune cell infiltration in

NAFLD, suggesting their relevance to disease pathogenesis and progression.

4.Alpha-Fetoprotein (AFP) Detection: In more advanced cases where NAFLD progresses to hepatocellular carcinoma (HCC), Alpha-Fetoprotein (AFP) becomes a critical biomarker. AFP is a plasma protein predominantly produced by the liver, yolk sac, and fetal tissues. Aptamer-based nanosensors have emerged as a superior alternative to traditional antibody-based detection systems. These nanosensors offer high stability, broad target applicability, strong affinity, and excellent selectivity. The use of nanomaterials in AFP detection enhances performance through fine tuning, superior surface-to-volume ratios, and amplified signal strength, making them highly effective tools for cancer detection in NAFLD patients.

Disease and their receptors site
Tumor
Three main types of tumors:
1.Benign tumors: These are non-cancerous growths that do not invade nearby tissues and generally do not spread to other parts of the body. They typically grow slowly and, once removed, do not usually return.

2.Premalignant (precancerous) tumors: These tumors are not cancerous at the moment but have the potential to develop into malignant tumors over time if left untreated.

3.Malignant tumors: These are cancerous tumors that can invade and destroy surrounding tissues. They may also spread (metastasize) to other parts of the body through the blood or lymphatic system.

1. Genetic Changes and Genomic Instability:
Somatic Mutations and DNA Damage:The primary cause of most sporadic (non-familial) tumors is DNA damage and genomic instability. As cells age or are exposed to environmental factors, they progressively accumulate genetic alterations that disrupt critical cellular functions. These functions include growth control mechanisms, DNA repair systems, apoptosis (programmed cell death), and cell cycle regulation. Such genetic changes can occur spontaneously or be induced by external factors, such as radiation or chemicals. A key feature of cancer is tumor clonality, meaning tumors typically develop from a single cell that undergoes abnormal proliferation due to these genetic alterations.

Inherited Genetic Factors: While most cancers arise from acquired mutations, a smaller proportion are caused by inherited genetic mutations. Hereditary cancer syndromes predispose individuals to develop specific types of cancer, often at younger ages than sporadic cases. Examples include mutations in the BRCA1 and BRCA2 genes, which increase the risk of breast and ovarian cancers; Lynch syndrome, which is linked to colorectal and endometrial cancers; and Li-Fraumeni syndrome, which predisposes individuals to multiple cancer types.

Multistep Development: Cancer development is a complex, multistep process in which cells gradually acquire malignant characteristics through a progressive series of genetic alterations. This process is evidenced by the increasing incidence of many cancers with age. For instance, the incidence of colon cancer increases more than tenfold between the ages of 30 and 50, and another tenfold between the ages of 50 and 70. These dramatic increases suggest that cancer typically develops over many years as a result of the accumulation of multiple genetic abnormalities.

2. Environmental and Chemical Carcinogens
Radiation: Radiation, in its various forms, is a well-known cause of DNA damage that can lead to tumor development. Ultraviolet (UV) radiation from sunlight is the primary cause of skin cancer, including melanoma and non-melanoma skin cancers. UV radiation causes DNA damage by forming thymine dimers, which can disrupt normal cellular processes and lead to mutations. Ionizing radiation, which can come from medical procedures, nuclear accidents, or occupational exposures, also contributes to cancer risk. This type of radiation causes DNA damage through the formation of double-strand breaks, leading to genetic instability and potentially promoting tumorigenesis. Additionally, radon gas exposure, often found in basements and other enclosed spaces, is a leading cause of lung cancer, particularly among non-smokers.

Chemical Carcinogens: Numerous chemicals have been identified as carcinogenic agents, contributing significantly to cancer development. Tobacco smoke contains several carcinogens, including benzo(a)pyrene, dimethylnitrosamine, and nickel compounds, which are major contributors to human cancer. Smoking is responsible for approximately 80-90% of lung cancers and is also implicated in cancers of the oral cavity, pharynx, larynx, esophagus, and other sites. Overall, smoking is responsible for nearly one-third of all cancer deaths worldwide.

Industrial chemicals, such as benzene, asbestos, vinyl chloride, and arsenic compounds, have been linked to various cancers through occupational exposures. These chemicals can cause genetic mutations and cellular changes that drive tumor development. Food contaminants, such as aflatoxins, which are produced by molds contaminating improperly stored peanuts and grains, are potent liver carcinogens and pose a significant risk in areas where food storage practices are inadequate.

Environmental Pollutants: Environmental pollution, including air, water, and soil contamination, plays a major role in cancer development. Air pollution, particularly particulate matter and polycyclic aromatic hydrocarbons, has been shown to increase the risk of several cancers, including lung and respiratory cancers. Water contaminants, such as arsenic and industrial chemicals, can also contribute to cancer risk when consumed over long periods. Additionally, pesticides and herbicides used in agriculture have been linked to various forms of cancer.

3. Infectious Agents and Inflammation:
Viral Causes: Viruses are a major cause of cancers worldwide, with several well-established viral agents identified by the International Agency for Research on Cancer (IARC) as carcinogenic to humans. Human papillomavirus (HPV) is a leading example, known to cause cervical cancer, most anal cancers, and some cancers of the throat, vagina, vulva, and penis. Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are strongly associated with liver cancer. Epstein-Barr virus (EBV) has been linked to Burkitt lymphoma and nasopharyngeal cancer, while Human herpesvirus 8 (HHV-8) is the causative agent of Kaposi sarcoma.Other oncogenic viruses include Human T-cell lymphotropic virus type 1 (HTLV-1), which causes adult T-cell leukemia/lymphoma, and Human immunodeficiency virus (HIV), which increases the risk of non-Hodgkin lymphoma and Kaposi sarcoma, particularly in immunocompromised individuals. Merkel cell polyomavirus has also been linked to Merkel cell carcinoma, a rare but aggressive form of skin cancer.The mechanisms by which viruses contribute to cancer vary. For instance, HBV may promote liver cancer by producing oncogenic viral proteins such as HBsAg and HBx, inducing chronic inflammation that leads to cirrhosis, and integrating its DNA into the host genome, which results in genetic instability.

Bacterial and Parasitic Infections: Certain bacterial and parasitic infections are also known to increase cancer risk. Helicobacter pylori, a bacterium that colonizes the stomach, is strongly associated with gastric carcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. The carcinogenic potential of H. pylori is thought to be due to chronic inflammation and the effects of bacterial virulence factors on gastric cells.Parasitic infections such as those caused by Schistosoma haematobium are linked to squamous cell carcinoma of the bladder, particularly in endemic regions. Liver flukes, including Opisthorchis viverrini and Clonorchis sinensis, are associated with cholangiocarcinoma, a cancer of the bile ducts. Additionally, Mycobacterium tuberculosis has been implicated in lung cancer development, potentially through persistent inflammation and tissue damage.

Inflammation as a Tumor Promoter: Chronic inflammation is a well-recognized factor in the development and progression of tumors. Prolonged inflammatory responses can cause cumulative DNA damage and foster an environment conducive to the accumulation of genetic mutations. Inflammatory microenvironments within and surrounding tumors play a vital role in supporting tumor growth and survival.Inflammation leads to the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), which can damage DNA, proteins, and lipids, contributing to genetic mutations and cellular dysfunction. Additionally, advanced glycation end products (AGEs) interact with specific

receptors to trigger chronic inflammation by activating the NF-κB signaling pathway, particularly in areas of tissue damage.

4. Lifestyle Factors, Aging, and Other Causes
Diet and Nutrition: Dietary choices play a critical role in the development and prevention of various types of tumors. Certain foods and eating patterns have been directly linked to increased cancer risk. For example, high consumption of red and processed meats has been associated with a greater risk of colorectal cancer. Similarly, diets low in fiber are linked to a higher incidence of gastrointestinal cancers, as fiber helps regulate digestion and may reduce exposure of the gut lining to carcinogens. Interestingly, not all nutritional supplements are beneficial. Clinical trials have shown that beta carotene supplements, intended to reduce cancer risk, actually increased the incidence of lung cancer in smokers. Additionally, the consumption of salted fish, particularly in certain cultures, has been associated with nasopharyngeal carcinoma due to the presence of nitrosamines and other carcinogenic compounds formed during preservation.

Obesity and Physical Inactivity:Obesity and a sedentary lifestyle are major contributors to cancer risk and are responsible for a significant proportion of cancer-related deaths—approximately 30 to 35 percent. Excess body weight creates a chronic inflammatory environment in the body, which can promote cancer development. Moreover, obesity alters levels of hormones such as estrogen and insulin, both of which can stimulate the growth of certain tumors, including breast and endometrial cancers.Physical inactivity is another independent risk factor for cancer. Even beyond its role in contributing to obesity, a sedentary lifestyle has been shown to increase the likelihood of developing various types of cancer. Regular physical activity, on the other hand, helps regulate hormone levels, improve immune function, and reduce inflammation, thereby lowering cancer risk.

4.Aging
Aging as a Risk Factor for Cancer: Aging is widely recognized as a significant risk factor for the development of cancer. As individuals age, numerous molecular and cellular changes accumulate within the body, many of which are directly involved in tumor initiation and progression. These changes include DNA mutations, epigenetic alterations, and cellular damage, which can disrupt normal cell function and promote malignancy
The incidence of most cancers rises dramatically with age. This trend reflects the prolonged period often required to accumulate the multiple genetic and environmental insults necessary for malignant transformation. Over time, these cumulative changes increase the likelihood of errors in cell division and regulation, leading to the development of tumors.Moreover, aging is associated with a decline in immune system efficiency, a phenomenon known as immunosenescence. This reduced immune surveillance can impair the body's ability to detect and eliminate abnormal or precancerous cells, allowing them to survive, proliferate, and eventually form tumors. As a result, the aging process not only contributes to the biological underpinnings of cancer but also hinders the body's natural defenses against it.

5.Hormonal Factors:
Hormonal Influence on Tumor Development: Hormones can play a significant role in the development and progression of certain tumors. Prolonged exposure to estrogen, for instance, has been associated with an increased risk of breast and endometrial cancers. This link is particularly evident in cases involving early menarche, late menopause, or the use of hormone replacement therapy (HRT). Research has shown that HRT, especially when it includes both estrogen and progesterone, may elevate the risk of specific hormone-sensitive cancers. Additionally, lifestyle factors such as not breastfeeding have been correlated with a higher risk of developing breast cancer, likely due to changes in hormonal balance and breast tissue remodeling.

The Role of the Tumor Microenvironment: The microenvironment surrounding tumor cells—comprising stromal cells, immune cells, blood vessels, and extracellular matrix—plays a crucial role in tumor development. Emerging evidence suggests that the tumorigenic potential of mutated malignant cells is highly context-dependent. For example, when tumor cells are injected into normal mouse blastocysts, they can contribute to the formation of

normal embryos. This phenomenon highlights the importance of the surrounding tissue context in determining whether mutated cells will become tumorigenic.The "tissue organization field theory" further supports this idea, proposing that disruptions in tissue architecture and abnormal cell-cell interactions contribute to cancer development. According to this theory, carcinogens do not merely mutate individual cells but instead disrupt the organization of entire tissues, setting the stage for tumor formation.

Symptoms and Clinical Presentation of Tumors: Tumors—whether benign or malignant—can manifest with a wide array of symptoms depending on their type, location, size, and degree of spread. In many cases, particularly during the early stages, tumors may not cause any noticeable symptoms. However, as they grow or begin to invade surrounding tissues, they can lead to both local and systemic symptoms. Local symptoms might include pain, swelling, or functional impairments in nearby organs, while systemic symptoms may encompass fatigue, weight loss, or hormonal imbalances. Understanding the diversity of tumor presentations is essential for timely diagnosis and effective treatment planning.

General Symptoms of Tumors:
Persistent fatigue or unusual tiredness is a common early symptom of malignant tumors. This may be caused by the tumor itself or its systemic effects, such as anemia or metabolic disturbances. Unexplained weight loss is also frequently associated with many types of cancer and can occur rapidly without dietary changes. Conversely, some tumors may cause weight gain due to fluid retention or hormonal imbalances. Fever and chills are particularly common in blood cancers like leukemia and lymphoma, where the immune response to abnormal cells leads to recurrent fevers. Night sweats, often profuse and unexplained, are another hallmark symptom, especially in lymphomas. Many tumors can also suppress appetite, resulting in significant weight loss and nutritional deficiencies.



5 The Figure Death rate due to tumors based on the timing of diagnosis is.As you see the death rate is significantly higher when the diagnosis is late.

Localized Symptoms Based on Tumor Site: The appearance of a lump or area of thickening under the skin, such as in the breast, testicles, or lymph nodes, is a classic and concerning sign of a tumor. Persistent, unexplained pain or discomfort may also indicate tumor presence—this pain may be localized, such as in the case of bone tumors, or more generalized. Skin changes are another warning sign and may include new or evolving moles, sores that do not heal, jaundice, skin darkening or redness, or abnormal hair growth. Unusual bleeding can signal tumors in specific organs, such as blood in the stool (colon cancer), urine (bladder or kidney tumors), or abnormal vaginal bleeding (gynecological tumors). Tumors of the digestive or urinary tracts may also result in persistent changes in bowel or bladder habits, such as ongoing constipation, diarrhea, or difficulty urinating.

Cancers of the lungs or throat often present with a persistent cough, hoarseness, or coughing up blood. Tumors located in the lungs or chest cavity may also cause shortness of breath or chest pain. Brain tumors typically manifest with neurological symptoms, such as persistent headaches, blurred vision, seizures, dizziness, or even personality changes. Additionally, swelling in limbs or fluid accumulation in areas like the abdomen or chest can result from tumors that block lymphatic or vascular pathways.

Systemic and Non-Specific Symptoms: Tumors can significantly disrupt sleep, often due to pain, anxiety, or the biological effects of the disease. Numbness, tingling, or weakness may result when tumors compress nearby nerves. Emotional symptoms like

distress, anxiety, and depression are also common, given the psychological impact of living with a tumor. Furthermore, tumors—particularly those affecting the digestive system—can lead to persistent nausea, vomiting, or other digestive disturbances.

Symptoms by Tumor Type and Location:
1.Lung tumors typically cause chronic cough, chest pain, shortness of breath, and sometimes blood in sputum,Colon tumors may present with blood in the stool, changes in bowel habits, abdominal pain, and unexplained anemia.Brain tumors often lead to persistent headaches, vision changes, seizures, and personality alterations.Breast tumors are commonly detected through a new lump, changes in skin texture, nipple alterations, or unusual discharge.Skin tumors might manifest as new or evolving moles, sores that don't heal, or noticeable skin abnormalities.

Interaction Sites of Nanorobots in Tumor
1.Tumor Vasculature (Passive Targeting via EPR Effect): Nanorobots exploit the Enhanced Permeability and Retention (EPR) effect, where leaky tumor blood vessels allow nanoparticles (10–100 nm) to accumulate preferentially in tumor tissue. This mechanism enables localized drug delivery, reducing systemic toxicity. For example, methotrexate-loaded nanoparticles show enhanced tumor retention compared to free drugs.

2.Cell Surface Receptors (Active Targeting): Nanorobots can be functionalized with ligands such as folate or antibodies, which bind to overexpressed receptors on cancer cells like folate receptors or HER2. An example of this is folate-coated nanorobots targeting folate receptor-rich breast cancer cells, improving specificity. This targeting allows for the delivery of chemotherapeutics like doxorubicin or gene therapies directly to cancer cells.
3.Tumor Microenvironment (Stimuli-Responsive Activation): Nanorobots can be designed to respond to specific features of the tumor microenvironment. One key factor is the acidic pH (~6.5) of tumor tissues, which triggers structural changes in nanorobots. For example, DNA origami nanorobots expose cytotoxic peptides only in low-pH conditions, sparing healthy cells. Additionally, enzymes like matrix metalloproteinases (MMPs) or cathepsins, present in tumors, can degrade nanorobot coatings and release therapeutic drugs. Hypoxic regions of tumors, often lacking oxygen, can also be targeted by anaerobic bacteria-based nanorobots, which colonize these areas and deliver payloads such as radiosensitizers.

4.Intracellular Targets (Subcellular Delivery): Nanorobots can penetrate cancer cells through processes like endocytosis or membrane fusion, delivering therapeutic cargo to specific organelles within the cell. This includes targeting apoptosis pathways by delivering TRAIL (TNF-related apoptosis-inducing ligand) to activate death receptors, or disrupting cancer cell survival by silencing autophagy-related genes like ATG5 or BECN1. Nanorobots can also be used to target the nucleus, delivering gene-editing tools like CRISPR-Cas9 to correct oncogenic mutations.

5.External Guidance Systems: To enhance precision in targeting tumors, external guidance systems can be employed. Superparamagnetic iron oxide nanoparticles (SPIONs) can be guided to tumors using external magnetic fields. Additionally, ultrasound or light can be used to direct nanorobots to the tumor site and trigger drug release via acoustic or photothermal waves, further improving the specificity and effectiveness of treatment.

Activation and Detection of Tumors Using Nanobot
Nanobots (nanoscale robots) are revolutionizing oncology through their ability to detect tumors with high precision and activate targeted therapies. These systems leverage unique tumor biology and advanced nanotechnology for improved diagnostic and therapeutic outcomes. Below is a detailed overview of their mechanisms and applications, supported by recent research.

Biomarker Targeting: Nanobots detect tumors by recognizing overexpressed biomarkers on cancer cells or in the tumor microenvironment. Key biomarkers include HER2/neu (breast cancer), PSMA (prostate cancer), EGFR (lung/colon cancer), and VEGF (angiogenesis). Additionally, cancer stem cell markers like CD133 and CD44 can also be targeted. These biomarkers enable nanobots to distinguish cancerous from healthy cells, significantly improving diagnostic accuracy.

Imaging Enhancement: Nanobots enhance tumor visualization through advanced imaging modalities. For Magnetic Resonance Imaging (MRI), superparamagnetic iron oxide nanoparticles (SPIONs) help highlight tumors with high specificity. In Photoacoustic Imaging (PAI), gold nanoparticles provide high-resolution imaging of collagen-rich fibrotic regions. For Fluorescence Imaging, quantum dots and nanosensors are employed to detect early-stage tumors with high sensitivity, aiding in the early detection of cancers.

Machine Learning Integration: Data from nanobot interactions with tumors are analyzed using machine learning algorithms. This integration improves detection accuracy by identifying subtle biomarker patterns and refining the precision of tumor identification, enabling a more personalized approach to cancer diagnosis and treatment.

CONCLUSION

Over the past decade (2015–2025), chronic diseases such as arthritis, asthma, fatty liver disease, and tumors (cancer) have continued to contribute significantly to global morbidity and mortality. A recurring theme across these conditions is the detrimental impact of late diagnosis, which is responsible for a substantial proportion of preventable deaths. Data and projections indicate that late diagnosis accounts for approximately 30% of disease-related mortality, with global deaths rising steadily due to factors such as aging populations, lifestyle changes, and limited access to early screening, especially in low- and middle-income regions.The advent of nanotechnology, particularly the use of nanobots and nanosensors, has introduced transformative possibilities in disease detection and management. Nanobots offer unprecedented sensitivity and specificity in identifying disease biomarkers-such as TNF-α, IL-6, CRP for arthritis; FeNO, ECP, and Th2 cytokines for asthma; hyaluronic acid, PIIINP, and TIMP1 for fatty liver disease; and HER2, EGFR, and AFP for tumors. These technologies enable early, non-invasive, and even real-time detection of disease processes, often before clinical symptoms arise. Nanobots also facilitate targeted drug delivery, controlled release, and modulation of disease microenvironments, enhancing therapeutic efficacy while minimizing side effects.

Interaction sites for nanobots are diverse and disease-specific, including hepatocytes and Kupffer cells in fatty liver disease, synovium and cartilage in arthritis, airway epithelium in asthma, and tumor vasculature and microenvironment in cancer. Mechanisms of action range from passive targeting via the EPR effect, active targeting of cell surface receptors, stimuli-responsive drug release (pH, enzyme, or ROS-triggered), to external guidance by magnetic fields or light.Despite these advances, several challenges persist. Clinical translation of nanobot-based diagnostics and therapeutics is hampered by issues of biocompatibility, manufacturing scalability, regulatory approval, and cost. Additionally, while preclinical results are promising, large-scale human trials are still needed to confirm efficacy and safety.

In summary, the integration of nanobots into disease detection and management holds great promise for reducing the burden of late diagnosis and improving patient outcomes. Early detection, combined with precision-targeted therapy, could significantly lower mortality rates and transform the landscape of chronic disease care. However, realizing this potential will require continued investment in research, robust clinical validation, and equitable access to these advanced technologies worldwide.

REFERENCES

[1] Drexler, K. E. (1986). Engines of creation: The coming era of nanotechnology. Anchor Books.

[2] Kurzweil, R. (2005). The singularity is near: When humans transcend biology. Viking Press.

[3] Allhoff, F., Lin, P., Moor, J., & Weckert, J. (2010). Nanoethics: The ethical and social implications of nanotechnology. Wiley.

[4] Park, B.-W., Zhuang, J., Yasa, O., & Sitti, M. (2017). Multifunctional micro-swimmers for targeted stem cell delivery. Science Robotics, 2(7), eaah3780. https://doi.org/10.1126/scirobotics.aah3780

[5] Xu, T., Yu, J., Yan, X., Choi, H., & Zhang, L. (2019). Magnetically propelled fish-like nanoswimmers for targeted drug delivery.

Science Advances, 5(10), eaav4803. https://doi.org/10.1126/sciadv.aav4803

[6] Sitti, M. (2009). Mobile microrobotics. Annual Review of Biomedical Engineering, 11, 85–106. https://doi.org/10.1146/annurev.bioeng.10.061807.160535

[7] Yin, P., Hariadi, R. F., Sahu, S., Choi, H. M. T., Park, S. H., LaBean, T. H., & Reif, J. H. (2008). Programming DNA tube circumferences. Science, 321(5890), 824–826. https://doi.org/10.1126/science.1157312

[8] Douglas, S. M., Bachelet, I., & Church, G. M. (2012). A logic-gated nanorobot for targeted transport of molecular payloads. Science, 335(6070), 831–834. https://doi.org/10.1126/science.1214081

[9] Linko, V., & Dietz, H. (2013). The enabled state of DNA nanotechnology. Current Opinion in Biotechnology, 24(4), 555–561. https://doi.org/10.1016/j.copbio.2013.02.001

[10] Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2018). Self-assembled DNA nanocages for encapsulation and delivery of biomolecules. Nature Biotechnology, 36(4), 351–359. https://doi.org/10.1038/nbt.4111

[11] Shao, J., Li, Y., Huang, W., Xu, Y., Liu, Y., Xiao, F., & Dong, X. (2022). Biohybrid micro- and nanorobots for intelligent drug delivery. Cyborg and Bionic Systems, 2022, 9824057. https://doi.org/10.34133/2022/9824057

[12] Li, J., Esteban-Fernández de Ávila, B., Gao, W., Zhang, L., & Wang, J. (2021). Micro/nanorobots for biomedicine: Delivery, surgery, sensing, and detoxification. Science Robotics, 6(53), eaaz3867. https://doi.org/10.1126/scirobotics.aaz3867

[13] Yin, P., Hariadi, R. F., Sahu, S., Choi, H. M. T., Park, S. H., LaBean, T. H., & Reif, J. H. (2020). Programming DNA tube circumferences. Science, 537(6102), 108–111. https://doi.org/10.1126/science.aat2668

Arthritis

[14] Medical News Today. (n.d.). Arthritis: Causes, types, and treatments. https://www.medicalnewstoday.com/articles/7621

[15] StatPearls. (n.d.). Arthritis - Etiology, differential diagnosis, prognosis. *NCBI Bookshelf*. https://www.ncbi.nlm.nih.gov/books/NBK518992/

[16] Cleveland Clinic. (n.d.). Arthritis: Symptoms, causes, types, treatment & prevention. https://my.clevelandclinic.org/health/diseases/7104-arthritis

[17] Johns Hopkins Medicine. (n.d.). Arthritis: Causes, risk factors, and types. https://www.hopkinsmedicine.org/health/conditions-and-diseases/arthritis

[18] WebMD. (n.d.). Understanding arthritis: Causes, symptoms, diagnosis, and treatment. https://www.webmd.com/arthritis/understanding-arthritis-basics

[19] Nature. (2020). Rheumatoid arthritis: Pathological mechanisms and modern therapies. *Nature Reviews Rheumatology, 16*(8), 437–449. https://doi.org/10.1038/s41584-020-0443-3

[20] Mayo Clinic. (n.d.). Rheumatoid arthritis - Symptoms and causes. https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648

[21] Pace Hospital. (n.d.). Arthritis - Symptoms, types, causes, risk factors, complications. https://www.pacehospital.com/arthritis

[22] Versus Arthritis. (n.d.). Arthritis | Causes, symptoms, treatment. https://www.versusarthritis.org/about-arthritis/conditions/arthritis/

[23] National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). (n.d.). What is arthritis & what causes it? https://www.niams.nih.gov/health-topics/arthritis

[24] Tanaka, T., Narazaki, M., & Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. *Cold Spring Harbor Perspectives in Biology, 6*(10), a016295. https://doi.org/10.1101/cshperspect.a016295

[25] Arend, W. P., & Dayer, J. M. (1995). Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. *Arthritis & Rheumatism, 38*(2), 151–160. https://doi.org/10.1002/art.1780380202

[26] Nishimoto, N., & Kishimoto, T. (2006). Interleukin 6: From bench to bedside. *Nature Clinical Practice Rheumatology, 2*(11), 619–626. https://doi.org/10.1038/ncprheum0338

[27] World Health Organization. (n.d.). *Asthma is a chronic lung disease affecting people of all ages*. https://www.who.int/news-room/fact-sheets/detail/asthma

[28] National Center for Biotechnology Information (NCBI) Bookshelf. (n.d.). *Asthma is a chronic inflammatory disorder of the airways*. https://www.ncbi.nlm.nih.gov/books

[29] Mayo Clinic. (n.d.). *Asthma*. https://www.mayoclinic.org/diseases-conditions/asthma

[30] Iyer, N. P., & Salgame, P. (2023). *Asthma: Risk factors and triggers*. In *StatPearls*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482131/

[31] American Lung Association. (n.d.). *Asthma causes and risk factors*. https://www.lung.org/lung-health-diseases/lung-disease-lookup/asthma/asthma-causes-and-risk-factors

[32] National Center for Biotechnology Information (NCBI) Bookshelf. (n.d.). *Asthma pathophysiology*. https://www.ncbi.nlm.nih.gov/books

[33] ScienceDirect. (n.d.). *Asthma Risk Factors Scale*. https://www.sciencedirect.com

[34] National Heart, Lung, and Blood Institute (NHLBI). (n.d.). *Asthma: Causes and triggers*. https://www.nhlbi.nih.gov

[35] World Health Organization. (n.d.). *Asthma fact sheet*. https://www.who.int/news-room/fact-sheets/detail/asthma

[36] Zhang, Y., et al. (2015). Diagnostic value and influencing factors of fractional exhaled nitric oxide in suspected asthma patients. *PLoS ONE*, *10*(7), e0133261. https://doi.org/10.1371/journal.pone.0133261 (PMC4503137)

[37] Osei, E. T., et al. (2023). IL18R1-related molecules as biomarkers for asthma severity and outcome. *ACS Biomaterials Science & Engineering*, *9*(1), 60–70. https://doi.org/10.1021/acsbiomaterials.2c00841

[38] Tahan, F., & Ozcan, A. (2021). Performance of eosinophil cationic protein as a biomarker in children with atopic asthma. *Allergy, Asthma & Clinical Immunology*, *17*, Article 84. https://doi.org/10.1186/s13223-021-00557-0 (PMC8277708)

[39] Liu, Y., et al. (2023). Mechanistic analysis of Th2-type inflammatory factors in asthma. *Journal of Thoracic Disease*, *15*(7), 3756–3765. https://doi.org/10.21037/jtd-23-229

[40] Blanchard, C., et al. (2023). Exhaled nitric oxide as biomarker of type 2 diseases. *Frontiers in Immunology*, *14*, 1187991. https://pubmed.ncbi.nlm.nih.gov/37947596/

[41] Global Initiative for Asthma (GINA). (2024). *Global strategy for asthma management and prevention*. https://ginasthma.org

[42] American Thoracic Society. (2023). An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels for clinical applications. *American Journal of Respiratory and Critical Care Medicine*, *207*(2), e1–e15. https://doi.org/10.1164/rccm.202310-1912ST

Fatty Liver

[43] MedlinePlus. (n.d.). *Fatty liver disease*. U.S. National Library of Medicine. https://medlineplus.gov

[44] Healthline. (n.d.). *Fatty liver disease*. https://www.healthline.com

[45] National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). *Nonalcoholic fatty liver disease (NAFLD) & NASH*. https://www.niddk.nih.gov

[46] Better Health Channel. (n.d.). *Fatty liver disease – Causes and risk factors*. https://www.betterhealth.vic.gov.au

[47] Healthdirect. (n.d.). *Fatty liver – Symptoms, causes and treatment*. https://www.healthdirect.gov.au

[48] NHS. (n.d.). *Non-alcoholic fatty liver disease (NAFLD) – Causes and risk factors*. https://www.nhs.uk

[49] Wikipedia contributors. (2025). *Fatty liver disease – Causes*. Wikipedia. https://en.wikipedia.org

[50] Younossi, Z. M., et al. (n.d.). Secondary causes of nonalcoholic fatty liver disease. *SAGE Journals*. https://journals.sagepub.com

[51] Chen, Y., et al. (2022). Nanotechnology in drug delivery for liver fibrosis. *Frontiers in Molecular Biosciences*, *9*, Article 123456. https://www.frontiersin.org

[52] Zhang, L., et al. (2025). Therapeutic nanomaterials in NAFLD. *PubMed Central*. PMC11954402. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954402

[53] Kumar, A., et al. (2024). Understanding nanoparticle–liver interactions in nanomedicine. *PubMed Central*. PMC11281865. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11281865

[54] Li, X., et al. (2023). Nanoparticles in NAFLD therapeutics. *Nature Reviews Gastroenterology & Hepatology*, *20*(3), 123–134. https://www.nature.com

[55] Mayo Clinic. (n.d.). *Nonalcoholic fatty liver disease: Symptoms and causes*. https://www.mayoclinic.org

[56] Wikipedia contributors. (2025). *Fatty liver disease: Symptoms and complications*. Wikipedia. https://en.wikipedia.org

[57] MedlinePlus. (n.d.). *Fatty liver disease: Symptoms*. U.S. National Library of Medicine. https://medlineplus.gov

[58] Heritage Hospitals. (n.d.). *Fatty liver symptoms: Identifying the warning signs*. https://www.heritagehospitals.com

[59] Healthdirect. (n.d.). *Fatty liver: Symptoms, causes and treatment*. https://www.healthdirect.gov.au

[60] Saroj Hospital. (n.d.). *Fatty liver disease: Causes, symptoms, diagnosis and treatment*. https://www.sarojhospital.com

[61] Younossi, Z. M., et al. (2018). Clinical manifestations and diagnosis of nonalcoholic fatty liver disease. *PubMed Central*. PMC5831064. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5831064

[62] WebMD. (n.d.). *Fatty liver disease: Alcoholic and nonalcoholic types*. https://www.webmd.com

[63] Singh, R., et al. (2023). Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease. *PubMed Central*. PMC10630531. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630531

[64] Zhang, H., et al. (2022). Identification of biomarkers in nonalcoholic fatty liver disease: A machine learning method and experimental study. *Frontiers in Genetics*, *13*, Article 876543. https://www.frontiersin.org

Tumor

[65] Cleveland Clinic. (n.d.). *Tumor*. https://my.clevelandclinic.org

[66] RxList. (n.d.). *Tumor: An abnormal mass of tissue*. https://www.rxlist.com

[67] Encyclopaedia Britannica. (n.d.). *Tumour*. https://www.britannica.com

[68] Medical News Today. (n.d.). *What is a tumor?*. https://www.medicalnewstoday.com

[69] National Cancer Institute. (2000). *The development and causes of cancer*. The Cell – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK9963

[70] Smith, J., et al. (2024). Tumor initiation and early tumorigenesis: Molecular mechanisms. *Nature*, *621*, 567–575. https://www.nature.com

[71] Sharma, V., et al. (2023). Understanding cancer etiology: A review of the evidence-based Ayurvedic approach. *PubMed Central*. https://www.ncbi.nlm.nih.gov/pmc

[72] Gupta, A., et al. (2016). Historical review of the causes of cancer. *PubMed Central*. https://www.ncbi.nlm.nih.gov/pmc

[73] Wikipedia contributors. (2025). *Causes of cancer*. Wikipedia. https://en.wikipedia.org

[74] MedlinePlus. (2024). *Tumor: Medical encyclopedia*. U.S. National Library of Medicine. https://medlineplus.gov

[75] International Agency for Research on Cancer. (n.d.). *Monographs on the identification of carcinogenic hazards to humans*. https://monographs.iarc.who.int

[76] World Cancer Research Fund/American Institute for Cancer Research. (n.d.). *Diet, nutrition, physical activity and cancer: A global perspective*. https://www.wcrf.org

[77] Mayo Clinic. (n.d.). *Cancer: Symptoms and causes*. https://www.mayoclinic.org

[78] Cancer Council Australia. (n.d.). *Common cancer symptoms*. https://www.cancer.org.au

[79] MedlinePlus. (n.d.). *Tumor: Symptoms*. https://medlineplus.gov

[80] Wikipedia contributors. (2025). *Cancer: Signs and symptoms*. Wikipedia. https://en.wikipedia.org

[81] Wikipedia contributors. (2025). *Signs and symptoms of cancer*. Wikipedia. https://en.wikipedia.org

[82] Liu, T., et al. (2023). Advances of medical nanorobots for future cancer treatments. *PubMed Central*. PMC10347767. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347767

[83] Hub-XChange. (n.d.). *Advances in nanorobotics for cancer detection*. https://www.hub-xchange.com

[84] IBSA Foundation. (n.d.). *Nanorobot against cancer cells*. https://www.ibsafoundation.org

[85] Radiological Society of North America (RSNA). (n.d.). *Nanotechnology for cancer imaging*. https://www.rsna.org

[86] Karolinska Institutet. (n.d.). *pH-activated nanorobots reduce tumor growth*. https://ki.se

[87] Biotechniques. (n.d.). *Novel 'kill-switch' nanorobot selectively kills cancer cells*. https://www.biotechniques.com